-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WVxt9KCMAsrExcFAZp18rXOi/4R9sYRF8iCRKSJDWJHPSxIBpUFq3ZopG59Jw1rL
 qSEfWu5jnugMU9WNFXGPyQ==

<SEC-DOCUMENT>0001193125-08-250632.txt : 20081210
<SEC-HEADER>0001193125-08-250632.hdr.sgml : 20081210
<ACCEPTANCE-DATETIME>20081209190701
ACCESSION NUMBER:		0001193125-08-250632
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20081210
DATE AS OF CHANGE:		20081209
EFFECTIVENESS DATE:		20081210

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NUVELO INC
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		081239533

	BUSINESS ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211
		BUSINESS PHONE:		650-517-8000

	MAIL ADDRESS:	
		STREET 1:		201 INDUSTRIAL ROAD
		STREET 2:		SUITE 310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070-6211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ddefa14a.htm
<DESCRIPTION>DEFINITIVE ADDITIONAL MATERIALS
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Additional Materials</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="4"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Washington,&nbsp;D.C. 20549 </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SCHEDULE 14A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>(RULE 14a-101) </B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>INFORMATION REQUIRED IN PROXY STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="3"><B>SCHEDULE 14A INFORMATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>SECURITIES EXCHANGE ACT OF 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="56%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#254;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed by the Registrant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filed by a Party other than the Registrant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Preliminary Proxy Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="2"><FONT FACE="Times New Roman" SIZE="2"><B>Confidential, For Use of the Commission Only (as<BR>permitted by Rule&nbsp;14a-6(e)(2))</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Proxy Statement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#254;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Definitive Additional Materials</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT FACE="Times New Roman" SIZE="2">Soliciting&nbsp;Material&nbsp;Pursuant&nbsp;to&nbsp;&#167;240.14a-12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>(Name of Registrant as Specified in Its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="1"><B>(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Payment of Filing Fee (Check the
appropriate box): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#254;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">No fee required. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee computed on table below per Exchange Act Rules&nbsp;14a-6(i)(l) and 0-11. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Title of each class of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Aggregate number of securities to which transaction applies: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule&nbsp;0-11 (set forth the amount on which the filing fee is calculated and state how it
was determined): </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Proposed maximum aggregate value of transaction: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total fee paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Fee paid previously with preliminary materials: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount previously paid: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Form, Schedule or Registration Statement No.: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Filing Party: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Date Filed: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE WIDTH="99%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="95%"><HR SIZE="1" NOSHADE COLOR="#000000" ALIGN="left"></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">

<IMG SRC="g70446g59c65.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">To the Stockholders of Nuvelo, Inc.: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT
FACE="Times New Roman" SIZE="2">As you know, Nuvelo, Inc., or Nuvelo, is holding a special meeting of stockholders at 9:00&nbsp;a.m., Pacific Standard Time, on January&nbsp;7, 2009 at the offices of Nuvelo, located at 201 Industrial Road, Suite 310,
San Carlos, California (unless postponed or adjourned to a later date) in order to obtain the stockholder approvals necessary for: (i)&nbsp;a proposal to approve the issuance of Nuvelo&#146;s common stock pursuant to a merger with ARCA biopharma,
Inc., or ARCA, (ii)&nbsp;a proposal to approve an amendment to Nuvelo&#146;s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo&#146;s common stock, (iii)&nbsp;a proposal
to approve an amendment to Nuvelo&#146;s amended and restated certificate of incorporation to increase the number of authorized shares of Nuvelo common stock to 250&nbsp;million, and (iv)&nbsp;an adjournment of the special meeting, if necessary, if
a quorum is present, to solicit additional parties if there are not sufficient votes in favor of Proposals No.&nbsp;1 and No.&nbsp;2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2">On
or about November&nbsp;25, 2008, Nuvelo mailed to you a detailed proxy statement/prospectus/consent solicitation that contains a description of the proposed transaction. The attached first supplement to the proxy&nbsp;statement/prospectus/consent
solicitation contains additional information that further supplements the proxy statement/prospectus/consent solicitation. Nuvelo urges you to read this first supplement, together with the proxy statement/prospectus/consent solicitation previously
sent to you regarding the proposed transaction, carefully and in its entirety. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2">We are providing this first supplement to reflect that ARCA
and Mr.&nbsp;Joseph&nbsp;L. Turner have mutually agreed that Mr.&nbsp;Turner will not be joining ARCA or the combined company as chief financial officer due to reasons unrelated to ARCA&#146;s, Nuvelo&#146;s or the combined company&#146;s business.
As a result, Lee Bendekgey, currently senior vice president, chief financial officer and general counsel of Nuvelo, is expected to become chief financial officer and principal accounting officer of the combined company on a transitional basis. As
Mr.&nbsp;Bendekgey is now expected to be an executive officer of the combined company on a transitional basis, we are providing this supplemental information regarding Mr.&nbsp;Bendekgey and his compensation. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2">After careful consideration, Nuvelo&#146;s board of directors has unanimously approved the merger agreement and the proposals referred to above, and has
determined that they are advisable, fair to and in the best interests of Nuvelo&#146;s stockholders. <B>Accordingly, Nuvelo&#146;s board of directors unanimously recommends that stockholders vote FOR the issuance of Nuvelo&#146;s common stock
pursuant to the merger agreement, FOR the amendment to Nuvelo&#146;s certificate of incorporation to effect the reverse stock split, FOR the amendment to Nuvelo&#146;s certificate of incorporation to increase the number of authorized shares of
Nuvelo common stock to 250&nbsp;million and FOR an adjournment of the special meeting, if necessary, if a quorum is present, to solicit additional parties if there are not sufficient votes in favor of Proposals No.&nbsp;1 and No.&nbsp;2. </B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2"><B>Your vote is important. </B>Whether or not you expect to attend the special meeting in person, please complete, date and sign the proxy
card enclosed with the proxy statement/prospectus/consent solicitation or the first supplement and mail it in the postage-paid envelope to ensure that your shares will be represented and voted at the special meeting. <B>If you have already submitted
your proxy card and do not wish to change your vote, there is no need to submit another proxy card in response to this first supplement to the proxy statement/prospectus/consent solicitation</B>. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo is excited about the opportunities the merger brings to its stockholders, and we thank you for your consideration and continued support.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Yours sincerely, </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:54%; text-indent:-2%">

<IMG SRC="g70446g85d61.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Ted W. Love </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px; margin-left:54%; text-indent:-2%"><FONT FACE="Times New Roman" SIZE="2">Chairman of the Board and Chief Executive Officer </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:3%"><FONT
FACE="Times New Roman" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved the merger described in the proxy statement/prospectus/consent solicitation or Nuvelo&#146;s common
stock to be issued in connection with the merger or determined if the proxy statement/prospectus/consent solicitation or this supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2"><B>The proxy statement/prospectus/consent solicitation and this first supplement are not offers to sell any securities and they are not soliciting offers
to buy any securities in any state where the offer or sale is not permitted. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:3%"><FONT FACE="Times New Roman" SIZE="2">This first supplement is dated December&nbsp;10, 2008 and
is first being mailed to stockholders of Nuvelo on or about December&nbsp;11, 2008. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>IMPORTANT! </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>SUPPLEMENT NO. 1 DATED DECEMBER&nbsp;10, 2008 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>PROXY STATEMENT/PROSPECTUS/CONSENT SOLICITATION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>DATED NOVEMBER 25, 2008 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>NUVELO, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>201 INDUSTRIAL ROAD, SUITE 310 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SAN CARLOS, CA 94070-6211 </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SPECIAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>TO
BE HELD ON JANUARY 7, 2009 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>GENERAL INFORMATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">This first supplement is being mailed to the stockholders of record of Nuvelo, Inc., or Nuvelo, as of the close of business on November&nbsp;11, 2008. The following information supplements and should be read in
conjunction with the proxy statement/prospectus/consent solicitation dated November&nbsp;25, 2008 of Nuvelo relating to the proposed business combination of Nuvelo and ARCA biopharma, Inc., or ARCA, which Nuvelo previously mailed to you on or about
November&nbsp;25, 2008. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>For a discussion of significant matters that should be considered before voting at the special meeting of
stockholders, see &#147;Risk Factors&#148; beginning on page&nbsp;28 of the proxy statement/prospectus/consent solicitation. </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo
is providing this first supplement to the proxy statement/prospectus/consent solicitation dated November&nbsp;25, 2008 to reflect that ARCA and Mr.&nbsp;Joseph&nbsp;L. Turner have mutually agreed that Mr.&nbsp;Turner will not be joining ARCA or the
combined company as chief financial officer due to reasons unrelated to ARCA&#146;s, Nuvelo&#146;s or the combined company&#146;s business. As a result, Lee Bendekgey, currently senior vice president, chief financial officer and general counsel of
Nuvelo, is expected to become chief financial officer and principal accounting officer of the combined company on a transitional basis. As Mr.&nbsp;Bendekgey is now expected to be an executive officer of the combined company on a transitional basis,
we are providing this supplemental information regarding Mr.&nbsp;Bendekgey and his compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Bendekgey, 51, joined Nuvelo in
July 2004 as Senior Vice President and General Counsel. In August 2007, Mr.&nbsp;Bendekgey assumed the additional role of Chief Financial Officer, which he also held from July 2004 until November 2005. Prior to joining Nuvelo, Mr.&nbsp;Bendekgey was
employed by Incyte Corporation from 1998 to January 2004, where he held several executive positions, including executive vice president, general counsel, acting chief financial officer and acting general manager of information business. From 1993 to
1997, Mr.&nbsp;Bendekgey worked for Silicon Graphics, Inc. where he held a variety of positions in their legal group. Prior to his employment with Silicon Graphics, he served as a partner at Graham&nbsp;&amp; James (now Squire Sanders&nbsp;&amp;
Dempsey) where he specialized in intellectual property, corporate and commercial law and founded the firm&#146;s Palo Alto office. Mr.&nbsp;Bendekgey graduated magna cum laude with a bachelor of arts degree from Kalamazoo College and received his
J.D. from Stanford University. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo&#146;s Compensation Discussion and Analysis </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The discussion and analysis below relates to Mr.&nbsp;Bendekgey&#146;s service as Nuvelo&#146;s senior vice president and chief financial officer.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Overview of Nuvelo&#146;s Executive Compensation Program </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><I>Corporate Governance and the Role of the Compensation Committee. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Nuvelo&#146;s compensation committee assists its board of directors in fulfilling its fiduciary responsibilities with respect to the oversight of Nuvelo&#146;s affairs in the areas of compensation plans, policies, and
its programs, especially those regarding executive compensation and employee benefits. Nuvelo&#146;s compensation committee charter is publicly available on Nuvelo&#146;s web site at www.nuvelo.com in the section titled, &#147;Investors,&#148; under
the subsection titled, &#147;Corporate Governance.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s compensation committee&#146;s primary responsibilities are:
(i)&nbsp;to administer Nuvelo&#146;s 2004 Equity Incentive Plan, as amended; (ii)&nbsp;to approve all compensation decisions for Nuvelo&#146;s chief executive officer, or CEO, and all executive officers; (iii)&nbsp;to review and oversee compensation
decisions with regard to other Nuvelo executives; (iv)&nbsp;to administer Nuvelo&#146;s cash bonus program, including the determination of the bonus pool based on the achievement of goals established by Nuvelo&#146;s board of directors; and
(v)&nbsp;to review and approve the policies adopted by Nuvelo with regard to employee compensation and employee benefits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Kimberly
Popovits, as the chairperson, Mark L. Perry and James R. Gavin III, MD, PhD presently serve on the compensation committee, and all served as members of the compensation committee throughout 2007. On December&nbsp;20, 2007, Ms.&nbsp;Popovits was
appointed chairperson of the compensation committee, replacing Mr.&nbsp;Perry as chairperson. Nuvelo&#146;s board of directors has determined that all of its compensation committee members are &#147;independent&#148; directors under the Nasdaq
definition of independence. Mr.&nbsp;Perry, Ms.&nbsp;Popovits, and Dr.&nbsp;Gavin all have extensive experience in executive management in the biotechnology industry, including experience with compensation practices and policies. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo compensation committee has the authority to retain advisors. In 2007, at the recommendation of management, the compensation committee approved
the retention of Radford. At the Nuvelo compensation committee&#146;s direction, Nuvelo&#146;s compensation consultants provided advice to management and the Nuvelo compensation committee regarding Nuvelo&#146;s compensation practices in connection
with retention, executive and director compensation and equity awards for all employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In 2007, the Nuvelo compensation committee met
seven times. The chairperson of the meeting is responsible for approving the agenda for each meeting in consultation with management. Nuvelo&#146;s chief executive officer, its vice president of human resources, and its general counsel attend
compensation committee meetings, except for those portions of any meeting in which the Nuvelo compensation committee meets in executive session. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2"><I>Objectives of Nuvelo&#146;s Compensation Program. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">As a development stage pharmaceutical company, Nuvelo is committed to
building a sustainable business focused on the discovery, development, and commercialization of novel therapies for the treatment of acute cardiovascular conditions and cancer. To achieve this vision, Nuvelo has emphasized the recruitment of
executives with significant experience working at large biotechnology companies and major pharmaceutical companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Pharmaceutical
discovery, development, and commercialization require sustained and focused effort over many years. As a consequence, Nuvelo&#146;s compensation committee believes Nuvelo&#146;s compensation program must balance long-term incentives that create
rewards for the realization of this long-term vision with nearer term </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">compensation that rewards employees for the achievement of annual goals that further the attainment of Nuvelo&#146;s long-term vision. Nuvelo believes that
compensation should not be based primarily on the short-term performance of Nuvelo&#146;s common stock, which has been and continues to be highly volatile. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">To this end, the objectives of Nuvelo&#146;s compensation program are to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reward executives for Nuvelo&#146;s success in meeting its annual and long-term clinical development and other operational goals; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reward executives for their individual performance and achievement of their personal goals and those of the functional organizations that they manage; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">enable Nuvelo to attract and retain highly qualified executives with significant experience at larger biotechnology and pharmaceutical companies by providing a
competitive compensation package that includes long-term incentives that provide significant retentive value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman"
SIZE="2"><B><I>Elements of Nuvelo&#146;s Executive Compensation Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following are the elements of Nuvelo&#146;s executive
compensation program: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Base Salary </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Cash Bonus </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Stock Options </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Executive Change in Control and Severance Plan </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">401(k) Plan </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Medical, Dental, and Vision Plans </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Life and Disability Insurance </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Employee Stock Purchase Plan</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In
2007, Nuvelo completed the transition of all compensation decisions to a calendar year basis. Previously, Nuvelo made adjustments to individuals&#146; base salaries and annual performance option grants effective August&nbsp;1 of each year, following
annual performance reviews for each employee, and made bonus decisions following the completion of each calendar year and the assessment of corporate and individual goal achievement. Nuvelo determined that a calendar year decision on each of these
three principal elements of compensation would be preferable. A calendar year decision would more closely tie individual performance assessment to individual and corporate goal achievement, and would facilitate the consideration of an
employee&#146;s total cash and equity compensation in a more integrated fashion. As a consequence, in 2007 Nuvelo made annual performance option grants effective February&nbsp;1, rather than August&nbsp;1. In addition, merit compensation increases,
which were made effective August&nbsp;1, 2007, are intended to be effective without change until February&nbsp;1, 2009, at which point Nuvelo will have completed the transition to align all compensation decisions with a calendar year schedule.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Executive Compensation Determination Procedures and Policies </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s compensation committee approves Nuvelo&#146;s policies regarding executive compensation, approves all compensation actions with regard to
Nuvelo&#146;s executive officers, and oversees all other aspects of Nuvelo&#146;s employee compensation programs. The Nuvelo compensation committee reviews executive compensation annually. In these reviews, the Nuvelo compensation committee refers
to performance assessments of individual executives, which for executives other than the CEO are generated by each executive&#146;s direct manager and reviewed by both the vice president of human resources and the CEO. In the case of the CEO, the
Nuvelo compensation committee evaluates his performance against goals established by the board of directors. In </FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2">addition, for each executive officer, the Nuvelo compensation committee considers Nuvelo&#146;s performance against annual and longer term objectives, market
data regarding executive compensation at relevant comparable companies, and the recommendations of management. For the 2007 fiscal year, the compensation committee approved the retention of Radford to assist management and the Nuvelo compensation
committee in analyzing and determining the compensation of Nuvelo executives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo determines executive compensation by reference to
publicly available compensation data from peer companies. As its primary comparison group for 2007, management and the Nuvelo compensation committee approved the following 14 biotechnology companies selected based on their stage of development,
their market capitalization, their therapeutic focus, the size and complexity of their organizations, and to some extent their geographic proximity to Nuvelo: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">ACADIA Pharmaceuticals Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Affymax, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Arena Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Cell Genesys, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Cytokinetics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Intermune, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Ligand Pharmaceuticals Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Mannkind Corporation </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Maxygen, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Metabasis Therapeutics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Peregrine Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Rigel Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">Telik, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">XOMA, Ltd. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo supplements
compensation from these peer companies with market data, taken from the Radford compensation survey, providing compensation information with regard to a large number of biotechnology companies with comparable numbers of employees and with expert
counsel received from Nuvelo&#146;s consultants at Radford. Generally, after management reviews the information generated by Radford and those of the selected peer companies, management and Radford make recommendations to the Nuvelo compensation
committee with respect to compensation for Nuvelo&#146;s executive officers and other Nuvelo officers. The Nuvelo compensation committee may accept or adjust such recommendations, and makes the sole determination with respect to Nuvelo&#146;s chief
executive officer and chairman of the Nuvelo board of directors. Members of management for whom compensation decisions are being made are absent from the meeting when the compensation committee is determining and deliberating his or her
compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For all executive officers other than the CEO, the vice president of human resources and the CEO make compensation
recommendations to the Nuvelo compensation committee based on the factors described above, including market data provided by Radford and the performance of the executive. In the case of the CEO, the vice president of human resources makes
recommendations regarding a range of potential compensation decisions to the compensation committee based on market data provided to her and to the compensation committee by Radford, and the compensation committee makes its decisions based on its
assessment of the data provided and its evaluation of the chief executive officer&#146;s performance. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Base Salary </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Base salary is intended to enable Nuvelo to attract and retain executives with greater than average
experience and skills, when compared to comparable biotechnology companies. For each executive position, Nuvelo sets as its target base compensation at the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT
FACE="Times New Roman" SIZE="2"> percentile of compensation paid by its peer companies for that position. Actual base salary may be below or above the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"> percentile, based on individual performance, experience, skills, and the importance of the position to Nuvelo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In July of 2007,
as in past years, Nuvelo conducted annual performance reviews of all of its employees, including Nuvelo&#146;s executive officers. Based on these reviews and the other factors described above, the compensation committee approved the aggregate total
adjustments to base salaries for employees which were effective on August&nbsp;1, 2007, which are intended to remain in effect until early 2009, when Nuvelo will complete the transition of its annual performance evaluation and compensation decisions
to coincide with the commencement of the calendar year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo compensation committee increased Mr.&nbsp;Bendekgey&#146;s annual
salary, effective as of August&nbsp;1, 2007, in light of the additional responsibilities he assumed as chief financial officer. The Nuvelo compensation committee further decided not to grant a merit compensation increase to the base salary of
Mr.&nbsp;Bendekgey. The Nuvelo compensation committee agreed the decision not to grant a merit increase was based not on its assessment of Mr.&nbsp;Bendekgey&#146;s performance, but rather on its conclusion that merit increases for senior executives
would be inappropriate in light of the impact of the reduction in force Nuvelo announced on August&nbsp;1, 2007. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Cash Bonus </I></B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Cash bonuses reward accomplishment of annual Nuvelo corporate goals critical to the achievement of its long term vision and the
individual&#146;s achievement of functional goals for the functional organization that he or she manages. The Nuvelo compensation committee determines cash bonuses by reference to target bonus amounts, based on market data, established for each
executive position. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">Nuvelo commenced its cash bonus plan in 2004. For 2004 and
2005, the target bonus for the Nuvelo CEO and other Nuvelo named executive officers was 25 percent of base compensation. This target amount is below the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman"
SIZE="2"> percentile for Nuvelo&#146;s peer group, which in some cases has resulted in total cash compensation below the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> percentile. Nuvelo
nevertheless considered these targets appropriate in light of Nuvelo&#146;s need to conserve cash and its reliance on the equity capital markets as its primary source of cash. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">In 2006, the Nuvelo compensation committee increased the target cash bonus for Nuvelo&#146;s
executive vice presidents and senior vice presidents to 35 percent of base salary. These targets were determined by reference to the target bonus percentages that Nuvelo&#146;s peer companies pay to executives in corresponding positions. While this
is still below the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> percentile for peer companies, this change is intended to help ensure that Nuvelo&#146;s total cash compensation is
competitive when compared to peer companies. It is also designed to increase the relative portion of each Nuvelo executive&#146;s cash compensation that is contingent on goal achievement, thereby increasing the performance-based component of each
Nuvelo executive&#146;s total compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo compensation committee determines each individual executive bonus by reference to
the achievement of corporate goals and the individual executive&#146;s achievement of functional goals for the functional organization that he or she manages. Nuvelo&#146;s board of directors sets annual corporate goals that fall into the following
categories: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">advancement of compounds in Nuvelo&#146;s research and clinical development pipeline; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">strengthening Nuvelo&#146;s financial position; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">development of a best in class organization capable of executing Nuvelo&#146;s vision. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">These goals included making &#147;go/no go&#148; decisions on all four alfimeprase indications. Given the
decision not to pursue some indications, the corporate goals were revised accordingly in August 2007. Enrollment goals for SONOMA-3, Nuvelo&#146;s clinical trial of alfimeprase for catheter occlusion, and CARNEROS-1, Nuvelo&#146;s clinical trial of
alfimeprase for the treatment of acute ischemic stroke, were included among the revised goals as were IND submissions for NU172 and NU206, and other goals that Nuvelo&#146;s board of directors determined were important to Nuvelo&#146;s progress and
were reasonably difficult to achieve. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo compensation committee determines the relative weight of each goal based on its
importance to Nuvelo&#146;s success. Given the importance of Nuvelo&#146;s research and development programs to its success, the Nuvelo compensation committee determined that achievement of goals associated with the advancement of Nuvelo&#146;s
research and development pipeline would be worth 70% of the total for bonus achievement in 2007, with financial goals afforded 10% of the total and organizational goals the remaining 20%. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">After the end of each year, the Nuvelo compensation committee establishes the overall bonus pool based on its assessment of whether Nuvelo has met
corporate goals at the target level, has exceeded expectations, or has failed to meet expectations. The compensation committee assessed Nuvelo&#146;s performance in 2007 as having achieved 84% of the target goal performance. The Nuvelo compensation
committee&#146;s determination was based on Nuvelo&#146;s failure to meet goals based on enrollment in Nuvelo&#146;s clinical trial of alfimeprase in acute ischemic stroke, as well as delays in the initiation of a Phase 1 trial of NU206. The Nuvelo
compensation committee found that Nuvelo had met other research and development goals, as well as its organizational and financial goals. The Nuvelo compensation committee&#146;s assessment of the percentage deductions for failure to achieve a
particular goal involves significant discretion, within the range of the percentages that the Nuvelo compensation committee has previously attributed as the value of the achievement of that goal. The Nuvelo compensation committee also retains the
discretion to grant bonuses to individual executives that are above or below the established target based on the above criteria and its subjective assessment of each executive&#146;s performance and the achievement of the corporate goals for which
that executive was primarily responsible. For that reason, following the determination that the overall bonus pool would be reduced to 84%, Mr.&nbsp;Bendekgey&#146;s bonus was calculated as 110% of 84%, because Nuvelo had met or outperformed all of
the finance, compliance and legal goals for which he was responsible. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Stock Options </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo grants stock options to its executives, and to all of its employees, to provide long term incentives that align the interests of its work force
with the achievement of Nuvelo&#146;s long term vision to develop and commercialize pharmaceutical products. Given the time periods involved in pharmaceutical development, Nuvelo believes that these long term incentives are critical to Nuvelo&#146;s
success. The exercise price for options granted by Nuvelo is established as the market price of Nuvelo&#146;s stock on the date of the grant. The market price of Nuvelo&#146;s stock on the date of grant is determined by the average of the high and
the low sale price on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:3px;line-height:95%; vertical-align:top"><FONT FACE="Times New Roman" SIZE="2">The Nuvelo compensation committee
determines stock option grants for the Nuvelo CEO and each other Nuvelo executive officer. Target ranges for stock option grants are based on position, salary level, and competitive practices of peer companies, as reported to Nuvelo by its
compensation consultants. As with cash compensation, Nuvelo targets the 65</FONT><FONT FACE="Times New Roman" SIZE="1"><SUP>th</SUP></FONT><FONT FACE="Times New Roman" SIZE="2"> percentile for option grants at peer companies. Actual awards also
reflect individual performance and potential, as well as retention objectives. In addition, in 2007 equity awards were subject to dilution constraints established by the compensation committee by reference to guidelines recommended by proxy advisors
such as Institutional Shareholder Services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Options are granted to all Nuvelo employees, including Nuvelo executives, when they are hired,
and once each year in connection with annual performance reviews. New hire stock option grants are effective on the first day of the employee&#146;s employment with Nuvelo, and the exercise price for those option grants is the market price on that
date. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Based on the revised annual performance and compensation calendar, in January 2007, the Nuvelo
compensation committee approved annual performance stock options grants, which were effective on February&nbsp;1, 2007. Using the criteria noted above, consistent with his market based option ranges and performance, Mr.&nbsp;Bendekgey received
options to purchase 100,000 shares of Nuvelo common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Executive Change in Control and Severance Benefit Plan
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In 2004 Nuvelo&#146;s board of directors adopted the Executive Change in Control and Severance Benefit Plan, or Severance Plan,
which is applicable to employees at the level of vice president and above. The board of directors determined that companies considered peers at that time commonly offered benefits comparable to those offered under the Severance Plan. Given the risks
associated with the biopharmaceutical industry and the increasing frequency of acquisitions in the industry, the Nuvelo compensation committee continues to believe that this plan is necessary to attract and retain qualified executives. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Other Elements of Executive Compensation Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The remaining elements of Nuvelo&#146;s executive compensation program, like its broader employee compensation programs, are intended to make Nuvelo&#146;s overall compensation program competitive with those of its
peer companies, keeping in mind the constraints imposed by Nuvelo&#146;s reliance on capital markets as a primary source of cash. With the exception of the Severance Plan, all of the remaining elements of Nuvelo&#146;s executive compensation program
(including its 401(k) plan, medical, dental, and vision plans, life and disability insurance, and employee stock purchase plan) are available to all Nuvelo employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
FACE="Times New Roman" SIZE="2"><B><I>Allocations between Base Salary, Cash Bonus and Equity Compensation for Executives </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The
development and commercialization of pharmaceutical products involves a high degree of risk, particularly in the early stages of clinical development. It takes many years of clinical development to reduce this risk. Like most other biotechnology
companies that have not yet commercialized any products, Nuvelo has been heavily dependent on capital markets for cash. Given the limitations on Nuvelo&#146;s cash, and the long-term risks associated with Nuvelo&#146;s achievement of its vision,
Nuvelo has in recent years weighted its total compensation, for executives as well as the rest of its work force, toward equity, in order to minimize the use of cash while achieving total compensation packages that have allowed it to attract and
retain talented employees, including those in its executive ranks. Nuvelo believes that this strategy has been successful, as demonstrated by the backgrounds of its executives and other employees. </FONT></P> <P
STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Internal Revenue Code Section&nbsp;162(m) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Under Section&nbsp;162(m) of the Code, the amount of compensation paid to certain executive officers that is deductible with respect to Nuvelo&#146;s corporate taxes is limited to $1,000,000 annually. It is the
current policy of the Nuvelo compensation committee to maximize, to the extent reasonably possible, Nuvelo&#146;s ability to obtain a corporate tax deduction for compensation paid to Nuvelo&#146;s executive officers to the extent consistent with the
best interests of Nuvelo and its stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT FACE="Times New Roman" SIZE="2"><B><I>Insider Trading Policy </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo has insider trading policies in effect that prohibit its officers, directors and employees from: trading in Nuvelo&#146;s securities while
possessing material nonpublic information; providing material nonpublic information concerning Nuvelo to any outside person that is not authorized by Nuvelo to receive such information; trading in the securities of another company while possessing
material nonpublic information concerning that company; disclosing material nonpublic information concerning any other company to anyone who is not authorized by Nuvelo to receive it; providing trading advice about Nuvelo to anyone while possessing
material nonpublic information about Nuvelo; and trading in any interest or position relating to the future price of Nuvelo securities, such as a put, call, or short sale. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">The following table presents summary information concerning all compensation paid to or earned by Mr.&nbsp;Bendekgey in all capacities in the fiscal years ended December&nbsp;31, 2007 and 2006. References to options
in the following table refer to options of Nuvelo. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Salary</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Bonus<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option<BR>Awards<BR>($)(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Non-Equity<BR>Incentive Plan<BR>Compensation<BR>($)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>All Other<BR>Compensation<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Total</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">364,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">553,650</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">121,275</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">925</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,040,350</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT FACE="Times New Roman" SIZE="2">Nuvelo Senior Vice President, Chief Financial Officer and General Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">2006</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">352,917</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">686,499</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">126,449</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">450</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,166,315</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amounts reflect stock-based compensation expense recognized for financial statement reporting purposes for the years ended December&nbsp;31, 2007 and 2006, in accordance with
Statement of Financial Accounting Standards No.&nbsp;123 (revised 2004), <I>Share-Based Payment</I> (SFAS&nbsp;123R), and include amounts attributable to awards granted in and prior to 2007. Assumptions used in the valuation of stock options are
disclosed in Note&nbsp;1 to Nuvelo&#146;s Consolidated Financial Statements for the year ended December&nbsp;31, 2007 included in the proxy statement/prospectus/consent solicitation. Amounts shown above exclude the impact of estimated forfeitures
related to service-based vesting conditions. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These amounts reflects cash bonuses earned in 2007 and 2006 under the Nuvelo cash bonus program, as described in more detail in &#147;Nuvelo&#146;s Compensation Discussion and
Analysis.&#148; Cash bonuses that were earned in 2007 and 2006 were paid in February 2008 and 2007, respectively. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These amounts consist of contributions made by Nuvelo to Nuvelo&#146;s 401(k) Plan for Mr.&nbsp;Bendekgey. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Grants of Plan-Based Awards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table
shows information concerning estimated payouts under non-equity incentive plan awards and the grant of equity awards to Mr.&nbsp;Bendekgey in the fiscal year ended December&nbsp;31, 2007. References to options in the following table refer to options
of Nuvelo. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Grant</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Approval</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Estimated Possible</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Payouts Under</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Non-Equity Incentive Plan</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Awards(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>All Other</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Awards:</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Number of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Securities</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Underlying</B></FONT><br><FONT
FACE="Times New Roman" SIZE="1"><B>Options (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>or Base</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Price of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Awards</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($/Sh)(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Grant</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Date Fair</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Value of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock&nbsp;and</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Awards(3)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Threshold</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Target<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Maximum</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">02/01/07</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">01/29/07</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">100,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">248,340</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">131,250</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount reflects the amount of cash bonus payable to Mr.&nbsp;Bendekgey under Nuvelo&#146;s cash bonus program if all 2007 corporate goals as well as his individual goals for the
functional organization that Mr.&nbsp;Bendekgey is managing have been accomplished. Mr.&nbsp;Bendekgey&#146;s actual cash bonus, which was approved by the compensation committee, was paid in February 2008 and is shown in the Summary Compensation
Table above. There are no threshold or maximum bonus amounts established under Nuvelo&#146;s cash bonus program, which is discussed in more details in &#147;Nuvelo&#146;s Compensation Discussion and Analysis.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">The exercise price of Nuvelo stock options is set at the fair value of a share of Nuvelo&#146;s common stock on the grant date. For stock options granted under the 2004 Equity
Incentive Plan, the fair market value is the average of the high and low prices of a share of Nuvelo&#146;s common stock as reported on Nasdaq for any applicable date. The exercise price indicated above was higher than the closing market price of
Nuvelo&#146;s common stock on the grant date of the related stock options. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Grant date fair value was determined in accordance with SFAS&nbsp;123R. Assumptions used in the valuation of stock options are disclosed in Note 1 to Nuvelo&#146;s Consolidated
Financial Statements for the year ended December&nbsp;31, 2007 included in the proxy statement/prospectus/consent solicitation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Holdings of Previously Awarded Equity </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth outstanding equity awards held by Mr.&nbsp;Bendekgey, as awarded under Nuvelo&#146;s equity incentive plans. References to
options in the following table refer to options of Nuvelo. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>2007 Outstanding Equity Awards at Fiscal Year-End </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number of Securities<BR>Underlying Unexercised<BR>Options (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Exercise</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Option</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Expiration</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares&nbsp;of&nbsp;Stock<BR>That Have Not<BR>Vested (#) </B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Market</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Value&nbsp;of</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Shares&nbsp;of</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Stock&nbsp;That</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Have Not</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Vested ($)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:22pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">106,771</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">18,229</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">8.41</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">07/11/2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">29,167</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">20,833</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.83</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">01/07/2015</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">87,500</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">62,500</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">9.17</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">08/01/2015</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16,667</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">33,333</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">16.74</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">08/01/2016</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">27,778</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">72,222</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">3.54</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">02/01/2017</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Mr.&nbsp;Bendekgey was granted these stock options on July&nbsp;12, 2004, at the commencement of his employment with Nuvelo. These stock options vest over four years: 1/4th vests 12
months after the date of grant and the remaining at a rate of 1/48th per month thereafter.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These stock options were granted on January&nbsp;7, 2005, and vest over five years at a rate of 1/60th&nbsp;per month.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These stock options were granted on August&nbsp;1, 2005, and vest over four years at a rate of 1/48th&nbsp;per month. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These stock options were granted on August&nbsp;1, 2006, and vest over four years at a rate of 1/48th&nbsp;per month. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">These stock options were granted on February&nbsp;1, 2007, and vest over three years at a rate of 1/36th&nbsp;per month. </FONT></TD></TR></TABLE> <P
STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Nuvelo Executive Change in Control and Severance Benefit Plan Applicable to Mr.&nbsp;Bendekgey </I></B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Severance Plan provides for the payment of severance benefits and/or change in control benefits to Nuvelo&#146;s eligible employees. All of
Nuvelo&#146;s employees at the level of vice president or above, including Mr.&nbsp;Bendekgey, have been designated by Nuvelo&#146;s board as participants in the Severance Plan. Nuvelo&#146;s board may designate additional individuals as
participants. To the extent a participant is entitled to greater benefits under his or her employment agreement with Nuvelo, such additional benefits supersede the benefits payable pursuant to the Severance Plan. As Nuvelo&#146;s senior vice
president, chief financial officer and general counsel, Mr.&nbsp;Bendekgey is eligible to participate in the Severance Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The Severance
Plan describes a &#147;change in control&#148; in Nuvelo as any one of the following events: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a sale or other disposition of all or substantially all of the assets of Nuvelo; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a merger, consolidation, or similar transaction involving Nuvelo where, immediately after the transaction, the stockholders of Nuvelo immediately prior to the
transaction do not directly or indirectly own, voting securities representing at least 50% of the combined outstanding voting power of the surviving entity; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">any person, entity, or group becomes the beneficial owner of securities of Nuvelo representing at least 50% of the combined voting power of Nuvelo&#146;s
then-outstanding securities, other than by virtue of a merger, consolidation, or similar transaction; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the individuals who, at the beginning of any period of two years or less, constituted the board of directors of Nuvelo cease, for any reason, to constitute at least
a majority of the board, unless the election or nomination for election of each new director was approved by the vote of at least a majority of the directors then still in office who were directors at the beginning of the two year period.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If a change in control occurs, all Nuvelo stock options and stock awards held by a Severance Plan
participant will become fully vested. The Nuvelo stock options and stock awards held by a Severance Plan participant will also become fully vested if the participant is terminated without cause or constructively terminated within one month preceding
Nuvelo&#146;s change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, if a participant is terminated without cause or constructively terminated one month before
or one year after a change in control, he or she will also be entitled to cash severance and benefits as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">payment equivalent to 12 months salary, paid over a 12-month period; </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">payment equal to the highest cash bonus received by the individual in any consecutive 11-month period within the preceding 36 months; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reimbursement of premiums paid for continued medical coverage pursuant to COBRA for up to 12 months. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In addition, if a participant is terminated without cause or constructively terminated outside the context of a change in control, he or she will be
entitled to 12 months of vesting of all stock options and stock awards held by him or her, and cash severance and benefits as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">payment equivalent to 12 months salary, paid over a 12-month period; and </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">reimbursement of premiums paid for continued medical coverage pursuant to COBRA for up to 12 months. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">For the purposes of the Severance Plan, &#147;constructive termination&#148; includes a material diminution in authority, position, or responsibilities,
a reduction in base salary, a change in the business location of more than 35 miles, a material breach by Nuvelo of any provisions of the Severance Plan, or any enforceable written agreement between Nuvelo and the participant, or any failure by
Nuvelo to obtain assumption of the Severance Plan by a successor. &#147;Cause&#148; includes a refusal or failure to follow the directions of the Board or individual to whom the participant reports, failure to perform duties in a satisfactory
manner, or crimes involving moral turpitude, fraud, or dishonesty. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B><I>Nuvelo Executive Officers&#151;Potential Payments upon Termination or Change in
Control </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The table below shows the potential payments and benefits to which Mr.&nbsp;Bendekgey would be entitled under the Severance
Plan. The amounts shown in the table assume that termination was effective as of December&nbsp;31, 2007 and that all eligibility requirements under the Severance Plan were met. While Mr.&nbsp;Bendekgey is expected to serve as chief financial officer
and principal accounting officer for a transitional period following the consummation of the merger, it is anticipated that his employment will be terminated following this transitional period and that he will be entitled to the benefits afforded
under the Severance Plan. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"> <P STYLE="border-bottom:1px solid #000000;width:27pt"><FONT FACE="Times New Roman" SIZE="1"><B>Benefits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Termination without Cause<BR>or Constructively<BR>Terminated</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Within the</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Context of</B></FONT><br><FONT FACE="Times New Roman"
SIZE="1"><B>Change in</B></FONT><br><FONT FACE="Times New Roman" SIZE="1"><B>Control</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Outside the<BR>Context of<BR>Change in<BR>Control</B></FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee&nbsp;Bendekgey</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash severance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">375,000</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">375,000</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Cash bonus</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">126,449</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Medical benefits</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">20,105</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">20,105</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Stock option vesting acceleration(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,153,315</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">625,210</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,674,869</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">1,020,315</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-top:3px double #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Amount represents the unrecognized fair value of unvested stock options that would be accelerated upon termination of employment as of December&nbsp;31, 2007. The fair value was
determined on the grant date of the respective options in accordance with SFAS 123R and, therefore, is not indicative of the value that would be ultimately realized by Mr.&nbsp;Bendekgey upon exercise of his options. As of December&nbsp;31, 2007,
the closing price of Nuvelo&#146;s common stock was $1.83, and the exercise prices of all stock options held by Mr.&nbsp;Bendekgey as of that date were above $1.83. Accordingly, Mr.&nbsp;Bendekgey would not receive any benefits from the acceleration
of stock option vesting as provided in the Severance Plan if the termination occurred as of December&nbsp;31, 2007. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo 2004 Equity
Incentive Plan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo&#146;s 2004 Equity Incentive Plan, or 2004 Plan, defines a &#147;change in control&#148; of Nuvelo as any of the
following events upon which the stockholders of Nuvelo immediately before the event do not retain immediately after the event, in substantially the same proportions as their ownership of shares of Nuvelo&#146;s voting stock immediately before the
event, direct or indirect beneficial ownership of a majority of the total combined voting power of the voting securities of Nuvelo, its successor, or the corporation to which the assets of Nuvelo were transferred: </FONT></P> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a sale or exchange by the stockholders in a single or series of related transactions of more than 50% of Nuvelo&#146;s voting stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a merger or consolidation in which Nuvelo is a party; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">the sale, exchange, or transfer of all or substantially all of the assets of Nuvelo; or </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">a liquidation or dissolution of Nuvelo. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">If a change in control occurs, the surviving, continuing, successor, purchasing, or parent corporation thereof may either assume all outstanding awards or substitute new awards having an equivalent value. In the event of a change in control
in which the outstanding stock options and stock appreciation rights are not assumed or replaced, then all unexercisable, unvested, or unpaid portions of such outstanding awards will become immediately exercisable, vested, and payable in full
immediately prior to the date of the change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">In the event of a change in control, the lapsing of all vesting conditions and
restrictions on any shares subject to any restricted stock award, restricted stock unit, or performance award held by a participant whose service with Nuvelo has not terminated prior to the change in control shall be accelerated effective as of the
date of the change in control. For this purpose, the value of outstanding performance awards will be determined and paid on the basis of the greater of (i)&nbsp;the degree of attainment of the applicable performance goals prior to the date of the
change in control or (ii)&nbsp;100% of the pre-established performance goal target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Any award not assumed, replaced, or exercised prior to
the change in control will terminate. The 2004 Plan authorizes the compensation committee, in its discretion, to provide for different treatment of any award, as may be specified in such award&#146;s written agreement, which may provide for
acceleration of the vesting or settlement of any award, or provide for longer periods of exercisability, upon a change in control. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Nuvelo 401(k) Plan
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">Nuvelo has a retirement savings plan, commonly known as a 401(k) plan, which is intended to be a tax qualified defined contribution
plan under Section&nbsp;401(k) of the Internal Revenue Code. The Nuvelo 401(k) plan allows all full-time employees to contribute from 1% to 60% of their pretax salary, subject to IRS limits. Nuvelo matches all employees&#146; contributions in an
amount of up to 2% of each participant&#146;s compensation in the year. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT FOLLOWING THE MERGER </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The following table sets forth certain information regarding the beneficial ownership of Nuvelo common stock immediately following consummation of the
merger with respect to Mr.&nbsp;Bendekgey and all directors and executive officers of the combined company as a group. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:89pt"><FONT FACE="Times New Roman" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>of Common Stock<BR>Beneficially Held</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="1"><B>Percent&nbsp;of<BR>Class(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">Lee Bendekgey(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">594,473</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">*</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT FACE="Times New Roman" SIZE="2">All Directors and Executive Officers as a Group (13 persons)(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2">78,807,895</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="right" COLSPAN="1" VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">49.03</FONT></TD>
<TD COLSPAN="1" NOWRAP VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&nbsp;*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Less than 1% ownership of Nuvelo&#146;s common stock following the merger </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Includes options to purchase 575,000 shares that are exercisable within 60 days of October&nbsp;31, 2008. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Assumes that 97,093,909 shares of Nuvelo common stock are issued to holders of ARCA capital stock in connection with the merger and 53,663,805 shares of Nuvelo common stock are held
by holders of Nuvelo common stock prior to the merger. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Total includes all directors and officers of the combined company, as previously disclosed in the proxy statement/prospectus/consent solicitation </FONT></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>THE SPECIAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>Date, Time and Place </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The date, time and place of special meeting of Nuvelo stockholders have not
changed and will be held on January&nbsp;7, 2009, at Nuvelo, Inc., 201 Industrial Road, Suite 310, San Carlos, California, commencing at 9:00 a.m. local time. Nuvelo is sending this proxy statement/prospectus/consent solicitation to you in
connection with the solicitation of proxies by the Nuvelo board of directors for use at the Nuvelo special meeting and any adjournments or postponements of the special meeting. This supplement to the proxy statement/prospectus/consent solicitation
is first being furnished to Nuvelo&#146;s stockholders on or about December&nbsp;11, 2008. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Purposes of the Nuvelo Special Meeting </B></FONT></P> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The purposes of the Nuvelo special meeting are: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">1. To consider and vote upon a proposal to approve the issuance of Nuvelo common stock pursuant to the Agreement and Plan of Merger and Reorganization, dated September&nbsp;24, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc.,
and ARCA biopharma, Inc., as amended by that Amendment No.&nbsp;1 to Agreement and Plan of Merger and Reorganization, dated October&nbsp;28, 2008, by and among Nuvelo, Inc., Dawn Acquisition Sub, Inc., and ARCA biopharma, Inc., and as described in
the proxy statement/prospectus/consent solicitation. A copy of the merger agreement was attached as <I>Annex A </I>to the proxy statement/prospectus/consent solicitation and a copy of the amendment to the merger agreement was attached as <I>Annex B
</I>to the proxy statement/prospectus/consent solicitation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">2. To consider and vote upon a proposal to approve an amendment to
Nuvelo&#146;s amended and restated certificate of incorporation in order to effect a reverse stock split of the issued and outstanding shares of Nuvelo&#146;s common stock as described in this prospectus/proxy statement/consent solicitation. A copy
of this proposed amendment to the Nuvelo amended and restated certificate of incorporation was attached as <I>Annex F</I> to the prospectus/proxy statement/consent solicitation. </FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">3. To consider and vote upon a proposal to approve an amendment to Nuvelo&#146;s amended and restated certificate of incorporation in order to increase
the number of authorized shares of Nuvelo common stock to 250&nbsp;million as described in this prospectus/proxy statement/consent solicitation. A copy of the proposed amendment to the Nuvelo amended and restated certificate of incorporation was
attached as <I>Annex G</I> to the prospectus/proxy statement/consent solicitation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">4. To consider and vote upon an adjournment of the
special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposals No.&nbsp;1 and No.&nbsp;2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">5. To transact such other business as may properly come before the special meeting or any adjournment or postponement thereof. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B>Recommendation of the Nuvelo Board of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THE NUVELO BOARD OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE
ISSUANCE OF SHARES OF NUVELO COMMON STOCK IN THE MERGER IS ADVISABLE TO, AND IN THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH ISSUANCE. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE &#147;FOR&#148;
PROPOSAL NO. 1 TO APPROVE THE ISSUANCE OF SHARES OF NUVELO COMMON STOCK IN THE MERGER. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THE NUVELO BOARD OF DIRECTORS HAS DETERMINED
AND BELIEVES THAT THE APPROVAL OF THE AMENDMENT TO NUVELO&#146;S AMENDED AND RESTATED CERTIFICATE </B></FONT>
</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">
<FONT FACE="Times New Roman" SIZE="2"><B>OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE ISSUED AND OUTSTANDING SHARES OF NUVELO&#146;S COMMON STOCK IS ADVISABLE AND IN THE BEST INTERESTS
OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH AMENDMENT. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 2 TO APPROVE THE AMENDMENT TO NUVELO&#146;S AMENDED AND RESTATED CERTIFICATE OF
INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF THE ISSUED AND OUTSTANDING SHARES OF NUVELO&#146;S COMMON STOCK. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THE NUVELO BOARD
OF DIRECTORS HAS DETERMINED AND BELIEVES THAT THE APPROVAL OF THE AMENDMENT TO NUVELO&#146;S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF NUVELO COMMON STOCK TO 250&nbsp;MILLION IS ADVISABLE AND IN
THE BEST INTERESTS OF, NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH AMENDMENT. THE NUVELO BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO. 3 TO APPROVE THE AMENDMENT TO NUVELO&#146;S AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF NUVELO COMMON STOCK TO 250 MILLION. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2"><B>THE NUVELO BOARD OF
DIRECTORS HAS DETERMINED AND BELIEVES THAT ADJOURNING THE SPECIAL MEETING, IF NECESSARY, IF A QUORUM IS PRESENT, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS&nbsp;NO. 1 AND NO. 2 IS ADVISABLE AND IN THE BEST
INTERESTS OF NUVELO AND ITS STOCKHOLDERS AND HAS APPROVED SUCH ADJOURNMENT, IF NECESSARY. NUVELO&#146;S BOARD OF DIRECTORS RECOMMENDS THAT NUVELO STOCKHOLDERS VOTE &#147;FOR&#148; PROPOSAL NO.&nbsp;4 TO ADJOURN THE SPECIAL MEETING, IF NECESSARY, IF
A QUORUM IS PRESENT, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF PROPOSALS&nbsp;NO. 1 AND NO. 2. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Voting and
Revocation of Proxies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">The proxy accompanying this first supplement to the proxy statement/prospectus/consent solicitation is solicited
on behalf of Nuvelo&#146;s board of directors for use at the special meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If you are a stockholder of record of Nuvelo as of the
record date referred to above, you may vote in person at the special meeting or vote by proxy over the Internet, by telephone or using the enclosed proxy card. Whether or not you plan to attend the special meeting, Nuvelo urges you to vote by proxy
to ensure your vote is counted. You may still attend the special meeting and vote in person if you have already voted by proxy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If your
shares are registered directly in your name, you may vote: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Over the Internet.</B>&nbsp;Go to the web site of Nuvelo&#146;s tabulator, Georgeson, Inc., at http://proxy.georgeson.com and follow the instructions you will
find there. You must specify how you want your shares voted or your Internet vote cannot be completed and you will receive an error message. Your shares will be voted according to your instructions. </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>By Telephone.</B>&nbsp;Call toll-free 1-877-816-0836 from the United States or Canada and follow the instructions. You must specify how you want your shares
voted and confirm your vote at the end of the call or your telephone vote cannot be completed. Your shares will be voted according to your instructions. </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>By Mail.</B>&nbsp;Complete, date and sign the enclosed proxy card and mail it in the enclosed postage-paid envelope to Georgeson, Inc., Wall Street Station, P.O.
Box 1101, New York, NY 10269-0666. Your proxy will be voted according to your instructions. If you do not specify how you want your shares voted, they will be voted as recommended by Nuvelo&#146;s board of directors. </FONT></P></TD></TR></TABLE> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>In Person at the Meeting.</B>&nbsp;If you attend the meeting, you may deliver your completed proxy card in person or you may vote by completing a ballot, which
will be available at the meeting. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">If your shares are held in &#147;street name&#148; for your account by a bank broker
or other nominee, you may vote: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Over the Internet or By Telephone.</B>&nbsp;You will receive instructions from your broker or other nominee if you are permitted to vote over the Internet or by
telephone. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>By Mail.</B>&nbsp;You will receive instructions from your broker or other nominee explaining how to vote your shares. </FONT></P></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>In Person at the Meeting.</B>&nbsp;Contact the bank, broker or other nominee that holds your shares to obtain a broker&#146;s proxy card and bring it with you to
the meeting.<B> A broker&#146;s proxy is</B><B><I> not</I></B><B> the form of proxy enclosed with this proxy statement. You will not be able to vote shares you hold in &#147;street name&#148; at the meeting unless you have a proxy from your broker
issued in your name giving you the right to vote the shares. </B> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">All properly executed proxies that are not revoked
will be voted at the special meeting and at any adjournments or postponements of the special meeting in accordance with the instructions contained in the proxy. If a holder of Nuvelo&#146;s common stock executes and returns a proxy and does not
specify otherwise, the shares represented by that proxy will be voted &#147;FOR&#148; Proposal&nbsp;No. 1 to approve the issuance of shares of Nuvelo&#146;s common stock in the merger; &#147;FOR&#148; Proposal&nbsp;No. 2 to approve an amendment to
Nuvelo&#146;s certificate of incorporation to effect a reverse stock split of the issued and outstanding shares of Nuvelo&#146;s common stock; &#147;FOR&#148; Proposal No.&nbsp;3 to approve an amendment to Nuvelo&#146;s certificate of incorporation
to increase the number of authorized shares of Nuvelo common stock to 250 million; and &#147;FOR&#148; Proposal&nbsp;No. 4 to adjourn the special meeting, if necessary, if a quorum is present, to solicit additional proxies if there are not
sufficient votes in favor of Proposals&nbsp;No. 1 and No.&nbsp;2 in accordance with the recommendation of Nuvelo&#146;s board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman"
SIZE="2">IF YOU HAVE ALREADY DELIVERED A PROPERLY EXECUTED PROXY CARD, YOU DO NOT NEED TO DO ANYTHING UNLESS YOU WISH TO REVOKE OR CHANGE YOUR VOTE. Each Nuvelo stockholder of record voting by proxy, other than those stockholders who have executed a
voting agreement and irrevocable proxy, has the right to revoke the proxy at any time before the polls close at the special meeting by sending a written notice stating that it would like to revoke its proxy to the Secretary of Nuvelo, by voting
again over the Internet or by telephone, by providing a duly executed proxy card bearing a later date than the proxy being revoked or by attending the special meeting and voting in person. Attendance alone at the special meeting will not revoke a
proxy. A beneficial owner of Nuvelo&#146;s common stock that holds shares in &#147;street name&#148; must follow directions received from the bank, broker or other nominee that holds the shares to change its voting instructions. <B>WHETHER OR NOT
YOU PLAN TO ATTEND THE MEETING, YOU ARE URGED TO VOTE BY PROXY TO ENSURE YOUR VOTE IS COUNTED.</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">15 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g70446g59c65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g70446g59c65.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0Q(4&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````.P```-L````&`&<`-0`Y
M`&,`-@`U`````0`````````````````````````!``````````````#;````
M.P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````":P````!````<````!X`
M``%0```G8```"9``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``>`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#T'ZS]9'1.AY?41M-M3-N.QW#KGGTL=KA+7.9ZKV^IM_P:YSZP?63K
M.?\`5&GKGU=L%-,./4VM:'Y%(:-MWI%TL;]F?O\`7_0[_0_6:=BCE?7CH.=E
M.Z)UWHUUN33>:AC^DS+8;6;F[Z&_S[G;';JWMQOYJQ=7TWHO2NF5VLZ?BLQ:
M\@AUM3-&$QM_FI]-KMOM?M24\3_SBZA]4_JOT.W8W-R^J%^5F'(>_>YKV^ON
M]?\`2.]5C;<:G>]EOT%U'U6^L[OK%BG)'3\C#K'%MNTTV'_NK;N;9>W_`(3T
M/35#ZY-^J6"[#ZE]8/TS<1CZ^G]-]I:]Q-;GN9C>QMNSTZ6?IW_8Z?\`"?X-
M9GU/^OF;U;ZPVX>>*Z<;,9_D^BL`BIU6Y[J3=#77/NH]^_Z'ZO\`HJV)*>L^
ML?4[ND]#S>I4-:^W%J-C&V3M)'[^WW(/U9^L5/7<%UA8<?.QG>EGX;I#ZK1_
M)=#O2L^G39_Z,KL0?KW_`.(_J_\`X6>L[KG1L_%LQOK7]7Z]_4\>EC<[#;H,
MS'`;NJ='TLJIH_0/^G^9^DV55I*=?I?6[LSK/6L"YC*Z>E/I;78)DBVKUWNM
MW>WV+6-E;6>H7`5Q.\D1'CN7G>+U+#ZK@?7GJ>$2[%R\.NRO<(</U)[;&/;^
M_7:U[%H=>:/_`!I@(T'3<6!\&T)*>T#V.<YK7`N9&YH.HG4;DM[-Y9N&\"2V
M=8/YT?)<AU`,Z#]:>G=<EM6#U>D=/ZB\D-:VUC?5P,FP_O;:W8V]W\W4LCJN
M1FL^J.?]80749'UDRJ1Z@]CZL`N&/A5[QO;7OQ&[GV_]W+$E/H%/4>GWWOQJ
M,JFW(J_G*66-<]L:>^MKM[5G876\C(^L_4NC/K8*,&FBVNP3O<;@XN#_`,WV
M[5SG4OJUU-_3ZZ>F=#Z=TC*PG,LP^H591WU&LASG/=]AJ?<RVL/9?Z]OZ3^<
MM1+\O(POK+];LRB&Y&/TNFVL\@/95<]GTOI>YJ2GKW=2Z<S+&$_*I;EN^CCF
MQHL,ZB*=WJ*QN;NVR-QX'=<;TWZM="R/J%4;Z*[+,O"^UWYKP'7&^RO[0_*=
MD']-ZM=K_I;O^#5GZOX&-]9OJETS(ZW6<C(LQO3?:7.:\MW-]QM8YEFZW[/6
MY_N]_P#UQ)3_`/_0U_K3]:^C?5[K&3=T[`;9U_):VN[,R&O96UK!M:UCK-CL
MCVM9N9A[*[?9ZV3^A6CC_6P=&^KW0LKKMKK[^JEIOO@--;;6OR?7=76UK/1Q
M]^/2]K?YNK])[_3]_1]2_9GV.S]J^A]CC]+]JV>E'_">M^C7`?7K$PLSJ?2V
M7YU73.B5XA^Q6MK?=ZDEAM^RU8S74MK93]C;ONMK_P""IN8DIN?6SZX=9Z+U
M,X>1@8F=TW*9ZN':[>-[/;ZM;Y]:IUM+W?F_X*RFQ:'U>Z)T+K>!A=>NZ-1T
MW*<X7X_V9Q80&._07N=0W%W>IM]38]EGZ)9_6\+ZIN^HF%B6]1NJPY'[+S\B
MNU]TC>[V4MJJN=CNQ_5K9^A]#[-Z7I?X!=M@_9?L6/\`8MOV3TF?9]GT?3VC
MTMG\GTTE(>M8&)U+I>3T_,L-./E,]*RQK@UP#R&C8ZP/9N<[^2CM?10P4FQH
M]&L..YP!#&^WU'_R?;]-4OK'5CW=*>S(O&*PW8Y;<YAL`L;?2[':ZII:YWJ7
MMKJ^E^>J'5L;!?=U+[;FMJO?T=U65%1+64S?OS0TNLW,W.L_5M[_`.;24DQ>
ME?5JA^=;5=4:/K$=EM`L8*K'0^F[[-LVNWW^K^FV6?SJIV?4?%?TP=$S>KYM
MO3"WT<7%<^IA;$O8SU64MNRO1:S]#3>ZVEC&?S/Z*OTR64]+=F]`LQ\FRMU=
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M]-WM;C=/R;*0VZ/YO&MM;57DYM7_`'6]7TW_`)^^M:=/2>ELZQF]3]7U+^HM
M9B7T/<QU?Z)KG>DVK;N]1U6Y]M;WO]BP,_!Z0_`Q&V=4KKH9T?T['_9R6V86
M[&_6L!N[;C96YM'I^G]I_26XOZM_1UL,IZ3_`,Y[+QD$Y)]GV0M/IC*%37/R
M&VN;Z?VYW2_0K]-C]_V/^VDIS6_5OI+.FVX='7KJ?JZ7&NS$;=0:V[G;WX;<
M]];LJJA^[8^C[1ZGI_X3](NIQJ*,?&JQ\9H9CTL:REC?HAC1MK:W^3M7)].Q
M.GCZM],IQ^HM=17E4'!R;<>[98]H`I8ZC(NW;+OI;Z'X^-_H5O\`U<JQ*>A8
M56%<<G&94!5>6[-[?WV5PW94[_`M;^C]+^;_`$:2G__9.$))300A``````!5
M`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P````$P!!
M`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P`````0`X0DE-
M!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("
M`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#L`VP,!$0`"
M$0$#$0'_W0`$`!S_Q`"3```"`P`#`0$`````````````"@<("04&"P0"`0$!
M`0$``````````````````0(#$```!P`!`@0#!`@"!@L````!`@,$!08'"``)
M$1(3%!46"B$B%Q@Q(R0E-7:X.30Z<3)2AB<:8D-39&765Y>WB!D1`0$``@,`
M`P$!`0$!```````!$0(A,4%1$C(B<6&!0O_:``P#`0`"$0,1`#\`?XZ"">2/
M)').)V3R^V;?8RU;/(*;IT%*2X)`Y6;NKK;86GQRR;(%4W#QNQ>3973P$`46
M1CVZZX)G!(2B62WB)/L-SK57IDYH4O)E^3Z[6).YR<S%M7T^7Y:B(I:;>R<<
MR@&TG)31?A;<RJ*3)%PNY^PJ)%#&*42%`.<OU1/\8H?`?._^W9?CUK\7_I3]
M_1<N]7_0HW=SZW_16BNIETFGRM?]./-[[R3C.5'.+DOI=TU>ZW6XU_$J9.7"
M2%5M!PU0C4[S=X^G0"!&L)5ZW*2ERAP%K%M6D>#B.,!$_.13P1-\3$C9;$.Y
M/P4Y$S[NH93R<RR8NS*;D:Z>BS<^2EW5W+Q3UQ'OF\)5[FG`S%F;IN6I_*YC
M$GC14@E435,0Y#&N6;+/%X>B#H#H*M;;S:XG<;KQ5,WWC><_RJ[7=BSE*O!7
M*44BEI6-?R[B!:R)'2C<T>V8GEFBJ)EEU4DTQ3,)Q*4!-T62WJ+1E,4Y2G(8
MIR'*!BF*(&*8I@\2F*8/$#%,`^("'Z>B/UT%:*/S'XP:3MMOXX47::;9MSH/
MQ_YQS2-<NSV2O_*T@TBK#\0049IMR?"9%^BBKY5#>!U`\/'HN+C..%E^B#H#
MH#H#H#H#H#H#H*O8QS3XK<B+]<,NQ/;Z5H^@T!M(/+E5*ZZ>+2M>:Q4TA79%
M:03<,FZ1"-)MRFV/Y3&_6&`/T?;T6RSN+0]$'0'0'0'0?__0?XZ!+WZJ+EL=
M[/85PHK4C^R0K8V]:HBW6`Q59>1+*U3,(9UZ8%,BM&199M^NW4,8%"2#)7RE
M$A#&E=-)W5T?IP.XX&_8BYX9:G.BXU[CU`I.LW?R3DRCZ[X>DZ2CV;%,QR>"
MLCE3QVWC3@)@,>)<L/(4XH.5`2IOKBY\9'=_[M)*<8KU)<Q./M9]/CQIM@,I
MI%5A&AO:8QHTXZ$XNT&B("2.SJ]2"PBS\A2MHN3.9E^J27CTAEC6NV>+V9=[
M=]&3X*=F_.YN302BIFE\9[UR5N2C[T$E$)RSUVQ;2\2ES*$%N16`CI!"//YP
M$I$F12F\WE$1LZ8VYVKS/EUUG*RSERLJX<.%5%UUUU#JK+K*G%1599503'45
M4.83&,81$1'Q'K+L:R[*>!]Z;01J]TH/(_2^.O$L/:*H3&S-`T^O6V"(<169
M8_CNBEDD%FST$"I&EVPPK$A#B9!VNJD9#JS+&UU^.3QC1)=%JV1<N3/7*3=%
M)P\,DD@9VNFF4JKDR"(%11,NH`F$I``I?'P#[.M.3Z.@2`^I;S:T[-W%>%N/
MT=!HZNNK9-2<VI[5^\2CF+FTWK<[?5Z^@]D%_P!2Q:+2THB518_W4B")A^P.
MI733B5<'L.=UBPN)`G;8YFOI.L;5FT@_HV+V*^G6C)R7"KK*Q3W"+H67])TU
MO]-78J-X85C>H_:)_#Q*1TU0]ZE\-M?_`*G1K[JN9-GMK_YD7GW_`/:?_P"5
MJ)U/72_B&N]%Y*<<\@M-?HVM;]BF77:V(M'-5I^BZI1:3:;,W?R*D.Q7K]?L
ML[&2TRB\ED3M4C-D5"J.2"F41.`EZK&+\)KZ(AIGR,X]R.K.\'C]VQI_N+#U
M_?8TST^D.M69^UB2SSGW>=H3A[>W]O!'*]4\[,/(T$%A\$Q\W1<7O'#CZ+RB
MXSZA>9;,,TY$X5HFE0))92=SRBZY0+;>85.`?)1DZI+5*`L$A/QQ(627(W=B
MLW(#9<Y4U/*<0#H8OPG7HB)8W?,*F=2E\-B-JR65VNOM#/Y['XW1Z<^U*$8D
M9L)`[V7S]K,JVR-:$82C5<5%FA"`BY2/X^50@B,7O'#Y-OY#X7QKJ(WO?-9H
M>25,RQFC67O-CCH(LJ^(D*YHR":.EBO[!+>@43@T9).'(D`3`00`1Z+);TIS
MG_>([96G6>.IU2YB94,_++)MHU"S'LE"8.W:ZA46[-*<OD!6H,7KI8Y2)(BY
M!54Y@*0HB(!TR?6_#2DIBG*4Y#%.0Y0,4Q1`Q3%,'B4Q3!X@8I@'Q`0_3T0E
M3].U_=([@'\FZK_416^I'3?J'.+5;*M1:[+V^[66OTZIU]DI(SUHM4S'5ZNP
MD>CX`J_EYN7<M(V-9)"8/,JLJ0A?'[1ZKFS8<=ZOM:-9P]>4YE9F9^1X5@9P
MWC[N[@Q7,8I0.2SM*HM6U&8";[7)78MP#Q$3@`"/4S&OKM\-&*'H-$U.IPU\
MS2YU;0*386P/(*W4N>B[-6YAJ(B7UXZ:AG3R/=D*<!*;R*#Y3`)1\!`0ZK+B
M9G8,DKDV]K5AU'.H*QQJ(N9&`F;M68N;8-RQI9D5WL4]DT'S5$(@P.A,HF4O
MMA!7Q\GWNAAS/S]1?7]M\Z5/W/Q_Y4]O\QP_K_-/P_XO\M>E[SU/C_PK]J]G
MX>X]O^L\GD^]T'__T7\T%T7**+ELLDX;N$DUT%T%"*HKHJD!1)9%5,3$424(
M8#%,41`0'Q#H,P.2O9J[>O+73K3M6UXS.3VL75:'5LUW8:]L,0[D4X"OL:O$
M,TX)K>OE",9,H:+:IE39QS</%`IA\1,IYYAJ;6<2H,Q+L&\*N-VX9SR#PBX<
MC\ST',YYI-PYX;3*])Q$JW!-RRGJW86=GH,\Y?UNXP3YQ&RB"2Z"BC)<X(J(
M*B"H,%VMF*V(T"@4O5*3:LWT:M1-QHEW@Y&M6NKSK4KR)G(25;G:OF#Q`W@(
MD52./E.42J)G`#D,4Y2F"LJD=Q?,-2U'@ER%Q3CY5FTUH>EYZUR:I5Q!_#UN
M+;15XFX.EV!PL\DEF47&05<IDJ]=N`*/G!HU.1!,ZHIIF+.+,LJNW/\`3Q\<
MN*",-K7*IQ7N1FX1B24NG&R;4PX3F[UJ4'`N(:O3"#96]2,>8#C\3GDBM"^!
M%4(UJND"YIAJ[V]=/IWSZBSB[G'+C(>.N4I1>D9>MH\=4=]Y!)2`DH5.AI,C
MF#(;.%6:A26M*M6!XU>RTP(FBR1C-=%B1ZHX(Y:LDTN,^F,NJP.@4,[S/]\S
MM$?SGQ;_`*OW'4O<=-?SLG;OS=I67VB/7YX<3HF1CN2>9-X^<TFNT]9S'S^D
MUVIE;K1MWJ0QWI.RZMGK=FFJ04%$W4E'-@(B)WK5HBX6)KMCB]+,=D3NTQG/
MG*AR+7Y9DQY99+!MC6<BIV3,-?IS846*&G0+%$K<I99LN=-"PLT4O2;.E47*
M?E1=E1;I4VUQSXS6[><2:%^I2YZ,S+@X%:'Y#RP*%3%,"EG[OF4Z1#RB8_B+
M8DB"8F\?O"3S>`>/@#UJ_B(U^HE_ND=O_P#DW*OZB+)TIIU3K'5<R;..?YK'
M5/\`?C^D^+ZGKI?Q$5=SBORO:G[T^*<\*<SD&60[Q8T]#N36,2<D:/'3HS>E
M\EZHF5,AR/Y";@YQ.QD!7U?+)S)3E('H)^"\4U_K6PX1M_(+/L*X\Z)R5L<H
MT?9YG^:RNF>]9/$@1L48UAQE(1C#/`*LDN[M:ZK=JP\I3^LNZ2`H&\P`-8DS
M<%\OI^\LG']-Y9]U[D.H8E[Y/VZ_2$=/.VZY@C<OK-@D;5HLM#E%`5TX&:O+
M,6:;9(QTDD*LW(D4I0`.I/EK?S6,X^$=(B>^KSWW3E/S:N"I..^(.(MOG6(R
MMM0K;`T1:9FP+9WFB*C1\Q51KT%`P#A[97,>=N[E955(QU0(X4`)VU?YF)VW
M8Y6]GKM?<@<7L-#H6?8+@^CMH&3#-=/S%W!5&0KUL]LJ:&=VMM!/V[>]UX[X
M")OFLFFZ5,T,I[91NX!)=.XC,VVE5!^FBY?:3I65;;P\U^7D)JP<6Y.OJ9\]
MFGJC^68Y]..)N`D*(+A91196)SVQ5LI6/F$WH-90C5,2H-D$R(;R<6*4_3M?
MW2.X!_)NJ_U$5OI%WZCD>[#IFB]R?NWXUVK:G<92LX=1K=6HB](P+E=1*?LR
MU/3U+5+H_9H_LLO(YYGC=:.B&SQ,Z3&1:/5/4(1TH)%[P:\:W8QTS[3O;C9X
MZ&&EX>8>O2/A98Q1^[ID<XT590&PM/CJFM*$_$\MK]$Q@"5)+%?D`PE(J4GW
M>KAC[7O)9WMU7;0>U)WFM![;KZWST[QPUJ^J5J!C)]RDH@WDKE3F=UPZ_,$R
MBC'%MLA'/(ZN32K/T$GIEC^HD95DV11G5PW?ZU^WICSEWVX:ARKONAW-_)52
MNFT;C5*8!,.`I35U9P=R^B4RR.[D2S(.V;X'Q:/67$`GX?KTVSOP!7T2BB:L
M2X9%?\O?R8^/_$O_`-"_W=\__CU[;\(U?B/YE?PU^5/Q5^)_-_G]E\T_M?P;
MR_#OA7[!Z?D^_P!3#7VGP__2KOW2:)R-[6'//1ZIQWV+9<5RC1WI]JQM/-K_
M`&RC0*-7NLF^>3-4;Q]9EF,4HSIMP2D(KVBI#B>/1;J+$$K@OFS>';7&TYG*
M[O:HYV=]KEYI"%'R/4(;2<TK;V/)HFE;_FU8E\_SV/6$#J?%;A7HRK7NS6:0
M:AXM(9O*N'KD0]3P;M@<.TTRFTUAY*'2ET(B+1GWT=)SR,<Q2FY*'BW,'$2$
MNFV2))/HN$>S%A>0\<[>`=1!JM(/E6Z1BIF<+&**AM.3D>@Z=H-]K&74BTZ)
M='CN/JE,A'U@GG<?#S-AD$HZ.1,LO["!KK"5GII\H`>5%JS;+NG"ABD33.<P
M%$//Q[LG?0VKFA(V7#<60M&$\96KMY%2D*LLM$:;K2"2HI&4TM=FM^XJ\L4G
MB6N-5#HCYC"^6=CZ1&^;7777'-[+Y]1MZ6'8GYK&YC\#Z,C:)=63UW`#-L6T
MM1XH*DA*(U]@B:@6YPH<3+/#6.E>V(Y=*"*CF59/3"(B'B.HX[3%;-]5DH9W
MF?[YG:(_G/BW_5^XZE[CIK^=C>?5<R8'>>[<FE\'-MC^ZKP(4>TB/A+>UM^K
MUVK-D#%RR[2CD6CO0(B&,@HR>YA?7+XS:?BU4UF[5V^4\2&CG9TF,ORZ:W,^
MM15V/>0CSE;WLMRY%25>;5.5UO"-'M<O76+I5['Q4RO)9"TEVT:Y<`#E2,&2
M:*F;>KXJE0,0#B8P"(R=KM,:X=Y^HI431[HG`)990B225*RQ1550Q2)IIDY#
M64QU%#F$"D(0H"(B(@``'5J:=4ZWU7,FSCG^:QU3_?C^D^+ZGKI?Q&SO?.X<
MAR_X`Z:A`1'Q'4L,(?<<T%N@121=KTYBZ/=JRV\J1WCGYFH2T@F@T2,7W$HB
MR$0,*92]*SK<4J_^?33N<W;LX,=J#.',D]W&W[:SQG0GBA7RJ*^/9R^KSO%E
M9(Y2"C\J-&MC0.],505&:6?J+*^DBL3S3_C>,6[>':+9QRA\_P"!MXXJXS$F
M)&0/%J[8QGT;Z:0.Y!TIF,O5HE=\+5)(CF8G)-<%W:P$`SAVNHH/WCCUISSF
MYI*+L$\(N#W.>Q<B\MY54Z3L.F4F/I5PSA@QOMQI3YS4U',_!Z`'L*Y-Q9'W
MP"9/"^J*J9E$O?@'CX>(!F.FULQ@RQ_RZ?:F_P#1"Y_^]>L?^:^KB,_?98C@
MWP;[>W#;8=OKG$5LC%:_%5FBQ&UU=33[5>9JKP-G4D[%1"3D/89N5+!'GBQ3
MEPW,!2*JI)"(_=$OB2VW&2\OT[7]TCN`?R;JO]1%;Z1K?J.LYU*IY%]5%80O
M;-&)3MVL:!%13J2(4#)J:KQTEC4%Y&G-]T5K&[G&+1,2CX^5\8GZ?$O4].]#
MOW6G,D7RD>I[#]4)C$#0FK:2>Y_IW'YE/KLC%,5RIFV>QNDW9TNHDG]]S7(!
M%PW6`1,)#,!((AY?`L]=)^#NG5<QT'__TVS>XOVO\0[D[3#6>NS=CJXXQ?)"
MP_%*BFS)/6.E6",(VMV>$D7OJ(PC:QR<3$.C/P0=+-@CS$23*9<54V%FUF49
M<D.<_;U[-6+0&0QS6!@9"O0G_#OC-D:;%_?9471!41F[&FN\\:^QF70BN\GY
M]R"[\P+*)>^<E%(TZ62[7+D>T#SCV+N'8;K'(_4:G6<]K[C=)^AY/0ZR9=^E
M"T:K5*G2!WDM8WH$?6:<?3UC=(.78HL4#G9>*+-N0?`Z&TQ<-282TUFRN+"U
MKMAA)US4IY6K6EO#RC*26KEF0C(N97KTXFS76/%3:,1-LW)VJX$7*@Z2.)0*
MH41K+-;D9WB^#G$?;YS`.1]QO^5WB$9UZ6*[D\GOE@K,Y`69F+R/L5<F:5#V
M?XQ#)>0Z"ZB:7G2=HK-_(*Z"R:<RU-;9F(<L/<Z['?)IJFSTK8.,VE-'22:)
M6^Y8_+))E246%J0BA-<S5A[0I#AXCY_)Z9/!0?`G@;IP8VGB)8_M8=B?G:WL
MS_`8G(9N9AO:*623XM;D\;R%0+,+/R1:DK1H"U3-2KJ,JK%N09B[@TR+E;J>
MCYBD-X,1?MM.T^<`>SOG';?VV[Z3@>\Z[,Y_I%+"JW+)-+;5.=;2,A'2J4K5
M;,A9ZU$TX4)&JBH^;M@4CEQ%M).2&/YC@8&,)=LSF-B.JRP/[AO;6Y$<H>Y=
MP)Y:YJ]SA#+.-=AQ.4T1O9K+*1=K6;9]OJNESP5R(:5R39R2IZZ<"MP5=M@4
M<_<$2%^_U&I9)8WPZK+BYR#AK/"3%:L<3'3U>L,7(0<]!S#)O(Q,U#2S19A*
M1,I'NTU6C^.D6+A1%=%4ADU4CF*8!`1#H%YN$_9SLG`WNKW[>,D39/>(%VQ2
M],*JD\G6A[/FUMM=FJ$@.:N8YTN$Q.0<<$(X5C9(I%1*P,D@Z4.Y2,NXF.6[
MMG7%[2/WONTW<.XE3LXT7#;!"07('$V\ZPA8>RO5HF!T*HS;AC)+UXT^BDY&
MO62&DX\7$2X4(#-11TLBY41*<CA!8FNV.^E7LDU+ZF>3ID1@DKQTX^U"Q1;1
MG6'O*S5K!3I>6CXY)H5HC:91G5-:M<';K.11'U57C.L2:*W_`%[$RIQ5%RN-
M.\CA+V9^7'&7NHM>7^DZ[6-JSDL==E[)I%DM$J?7+M;[SE+B#G9Q]5C5\\;&
ML5;Y)N0:-OBBXLXDB)/.H8@^+')=I=<&A3%*<IB'*4Y#E$IBF`#%,4P>!BF*
M/B!BF`?`0']/58+J=OKLGI\0NY+R0Y12C>N*X[''G?RCQ#.1*\DH`NIF5=VH
M\A'&;^XB#YU`NG598&56.9ZT>J+B`B!3!,<MW;,D,6]5@IWSK['/)+.^41^=
M':DN\?2=%<V.1O$MDJ]@CZ@_A[G+JN5K`YSF9GR!2)*H7$SQ8)"N3JK6/1*L
MLD119FL5FUF/ATFTQC9VJ)USZH'6HDN5FX]<<\*>'2&$EM]EE*(UEHPSKUVY
MI\R">PZ7!OU6_IF-ZD)4'A">!3`E]XGF<IC3Y;(=N/@@RX*X]/PEBODCL6]Z
M_;GNG<A]JFA?'DM!T&3%40*W/*.WTG\!KS9<R+8SA4RSI=1R\.1$[HR"5C-N
M?\9K]I?M7<FN$_-CE1R!V-_E[JB;+7KQ%U%&F6J7FY]-S8=9A[LP&8CW]7AF
MS)((9B<%!(X6$JW@4`$!\P21K;:63"0>[WV=YOFW::-R@XR7B,R?EYE:,.E'
MRDJ]D(6!O<?4Y%6?J1UIV&9OI&KW^I2YO-%2Q454U$Q(W<B1-)NNV6)KMCB]
M(.8<E_J16U'+DB_`K%'VI-XPL$'(-SH69)0BP%3(T+=UZXEL2527GQ;C[LZ2
M8$:BY\?W4!0%GTY7&G>4U=I+L]VOA]H5\Y=\L;_&:]S"U,E@!X^BG+V8@:&E
M<90TO<)$E@E6K!W9KY;G`$*]?D:-463<R[1L*R2ZJRJ1-ML\3IOQU61T'__4
M8E[P.S=VVFUAW4^`7'A64HS^+1)9MVH\M"7S9&:[I$BCJ(I.2J&1F8)5'RJ(
MFE$6,ZL8#>9`&*H)*FERUK]?:\\34&FH-+[9PVAM?6VH.)1R[N8:@C84;ZO-
MN#B=VYLX6LI;"I*+J>(J'=^*IC?:81'K+M_G3T>NQ72X[&.TSQTE9XZ4.2=@
M=(UZT2+OTD4$HZQWVWSD?*+F2%00;H4=NP$3&,8XD3\1`OV$+J=..WZI2G@_
MWH+UQM[AFU\A[DO.3G'SE7K=EL.UT(O[0[A(2>L\B\J=SK#$ICIEM.91$@5N
MFW(;R2,855F804%LX;S+I=<R3TRGWQN"U5[B?#.N\G>/IXR[:GCM06TO,YRK
MB1^36L8FV+>?LM48KLT%74NZ&,2+,02?WS@]26:ID(=^H8+6-;BXKSR^LNKT
M;OIX>)9>-O;[JE_G8LS+1.4,H?99]1PD!'K>E+HC$Y1$>H4P@K'*5)#XXCXE
M`Y%9]8AO'RAX:CCO<UN[U61T$-,N0.12.]3G&-G;?6W&N9I&[#,TCX#9T_9Y
MS,3YZO'6+YE5A25!Q[B=(*'M$I!1\3P\YD2I_?Z+CC/@U?D#D6'R^2P.HVWY
M8EMTTN(Q[+&GP&SS7S3HT\U>/(FN^O7H66;0GNVS!8WNY$[-BGY/`ZQ1$H",
M(]Y+<T^-O$%7/6W("]RU0>ZM(3\5GL;!9KJFF2UGD*NS82$\V9Q.5TF[22!X
M]C)HJF%=)(IR&$2";R'\HDMZ%KYI\;:)QA<\R+G>Y:K\=F;:*>/;O.9KJD;+
M,F\W=V.<Q9GF<.J2GJ#0[RXR2#4I%(4IP(J"Y@!MXK=#%SCUV/CWREQ;E)#6
M&?Q:<MDW%U:3:Q$TK;,GUO*'"#]XU%ZW3:1^MT:C2,LB9N'B99HDN@0WW3'`
MWV="RSM-=CL$14J]/6JP._A\#68:4L$V_P#;NG7LHB&8KR,D[]JR1<O7/MF3
M8Y_31345/Y?`A3&$`$B.,XWS)=:Q6#Y$T"WI3>-V2HN[W#W1>'L$&BYJ;!)X
MN\F%H:PQ,38V*3=%@L8R;AFDOX$_U/M#Q&,<.AN>97&5I@=!Y0.-9A"85J#N
M@Q]#OA8VQJI6*2TVPQ]5IT6WKZ4*>UM91W/21$';9PP17B?2<'?D;)M7)T2X
MN<>NX\@N1&/\6<QE-CW6V+4O.H:3K\-(3K:L6^XN$Y2TS+*O0#)"OT6`LUE?
M+24S((H%!!FJ!3'`3^4H"8!)GIUGC=R[XY\NH*S6'CSID?H#.E3@5JY,#0EI
MJ-GJ4Z=(ZR4=9Z9>8*LV^`6<$14](7;%(JID52D$QDE`*++.T)XCW1>"7(K2
M87(LEWAO.:%9G%D9U6!GL[UK/B6][3P?&M#&G3.C4.IP%M?0)8U<SE&-=.E4
MBI"(E\/`>ABSG"8^27,+C[Q,9T]7;;LYA)C1I9U`YQ2JU5+?H6A:#-,4D%GD
M=3Z'08*R6J:.T*[1!=9-K[9N9=(%5">H3Q$EO3[L<Y9\?]_R>R;7D%^+=J#3
M7%G87!6.K-P;VVJ35,:G>V:LV+.)"OL]%B+=&-B@?X2M%%D5RJ)BBBIZJ7G&
M++AU[\[_`!;/QMJ_+IOJK9_Q^NKFNQ]1N\55;U+O[)+6NY(Y[!04-0XRL.]&
MD+&[N:_L#QR<09\W535%9),B*IB#%SCU^.2W-_C-Q"E\TK^_7V9J<]L7SE^&
ML)7\OUO4)>U?A\U@7MQ]I&Y11;N]:_`V5F9+*>Y(AYTE#'3\Y4EA3$EO3MDS
MRGPRN\='O+"P6Z3@L&C:F-XD;A,T/1(R485DKH&1G[V@/:FAH[58')@*+52(
M*[\!\?2\OV]#%SCU&W'WN#\/N4=N5S[%=C;3]^3K@6]*C6>F:-EURD*H*I$?
MF2&J^K5"DSD[!E.H7Q=,D%T2E,!A,!1\>A98N;T0=!__U7^.@AS9N/&$<B:]
M\J[MC^<:Y`%*H#9AH%0A+.$<HJ42F=0[F49N'D*^`!^ZX:*(KD'[2G`?MZ++
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MJ7'>JX06[?V48W;5!A(S]>;F%%-1`RC-$`(Q.IU,<MS;^;\P\I!PD1682'K=
M?CFD/`U^+CX2$B6")6[&+B(EHBPC8YDW(`$0:,F3<B29`^PI"@`?HZTY.4Z`
MZ#$6_2=^P;N^Z/R&E>/W(S1LDMO!B@91$VW&<?LNE,/GEAKDG9WL,[4A4_2;
M*M(=OZBGB81**B8"'WPZGK7>LF4K=Q'.M'V"]=KRTY]GEUL,91N=V1ZA?RM*
M\_.\H%'0JUD&0GKHU33.>O,XE9^DB[.OY2H+&\AA\>GP3B;.F]S#C=JO(7E5
MVR`H+O:*96*5IG(![HFT8BG&M;/D,=-9=$MH.8-89ZLV^MU[Y@DF1H\BCV/<
M$6(JHF0`.)3E4UN)7)]W3C_J-R[1^W\?\M;ZKR(TWX'A$+#*/VS6W:SHBM6W
MK)9F9G9E*K04&QEISX+#NG[Y1I'M40(BHH"1"%\`7HUO]2K%\#)!R6M:%77=
MBY\7%>.G(6:^9N>='BJC93I3C!VQ)!9ZZA,_SR/EH.+/73.'J?M5UFKA\F)E
M?*NF0M2_^+1[M%24[B&R0<,Q<R<Q,Y5H<5%1K)$[AY(24C49=HQ8M$$P%1=R
M[=+%33(4!$QS``?IZ).XR<RJ@;SF'893RR.RR_DY"L^&%^SZ+R]O7'9M!97B
MV1%FK<:U)6EDP>&DXQ:<3=BB9,QO(D(^0W^J,\:X^W_&)VL]L3N"L<"U/A;&
MQ=]LG''B17EN5_&:0@R.I6=U#:M+:9\++&8IJFU:I2B61RBFAO"I(M_=@\ED
MS*E$KQJ)6&OM,Y],']SJCZOR&X%UF)H-%NRNBV;3^)MR>5:O5U5_;ZDFRU[/
M+1:7BT`^9R/H+4ADBX7=$=H+)H`U/ZQ3%*8!5G7BK1\8>'U+XR3>U7MI=+YJ
M>N<B[?#W;9M3T12J-INU2U=AA@JXP8UZ@U:DTFMP%>CEEB-&[.-(MX+G]=9<
M0()*EN?\+E\(.(G+'&="[;^G;CD&K7_&*1M7+6$-D"^?GC['Q4TG5+_834[D
M'*,H.+:6>UT*V0Y&YEEIHSMG`@!GB(E,HV(6-VS%^6H_-"J:=D_<IX;\W"9)
MK6UX12\?UC#[Q'XK19O5[QD]INBKMY#Z"3-:PTDK=+PD^W?%CW[J):+K-6S0
MPJ@/BBBN]9G.MF>7:^V+G>EGUSN#<I+AE-VPZC<KM^J]DR7-M-@'5,T8:W0:
M<I6I/0;717?E>T]UH<L\,Y*T>D1DA,@<ZZ?D,BHH+Y%5L%[?.Q4?N`2V)RT&
MX;]N#CWL$MS_`./K4[`Q(-UNNKQB=>I^5QSD$R-DX?!+>VMDZS9(+*KLA6BW
M#HH%D$!$MO&?4B=V;)=0N?+KMF:54(?E@TH62_G-_$S4>'511M>NYI\^9EG$
M#3/A19"J76&9?.4RU5CE_=1Z_J1@O?3\AR`J1?$UO%3CS`JEXVSM![51LZK'
M(J_7VQX=)5"O0.UTY2,Y'7.7@;&A"&?W.IQT'!>>S6'X.=\46\>U2=-EDUTT
MB$4*`/"?J*P4NJ[+R>YA=L:TP/&+;,5IG!7+[PKLFR;C2!R]:S2-RR"*SN.R
MS/HF0=_--M;A.1ZKAXL9--BB@H8_AXB!5GPO$FW/9@SJL#H/_]9_CH#H%^_J
M&/E;\OW%_P">/PT^5/S80'OOS`?C%^7+WWX6ZA\-_%#\O'_&CWOG]3X9\._=
MWI>]]_\`=]'J5O3NM+NWKZ'Y4,R]K^4+VWLG'M_R,?$?RX^AZA?2^3_B_P"]
MO>^GX>^]U^T>Y\WJ??\`-U6;VNMT1QC_`/Q4+_#/XFK_`(__`!7\&EOX+_XG
K_M_]S]?H.3Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z`Z#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g70446g85d61.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g70446g85d61.jpg
M_]C_X``02D9)1@`!`@$`8`!@``#_[0G84&AO=&]S:&]P(#,N,``X0DE-`^T`
M`````!``8`````$``0!@`````0`!.$))300-```````$````'CA"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))300*```````!```X
M0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&
M```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4`
M```!`"T````&```````!.$))30/X``````!P``#_____________________
M________`^@`````_____________________________P/H`````/______
M______________________\#Z`````#_____________________________
M`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`
M````.$))300:``````!M````!@``````````````/P```-@````&`&<`.``U
M`&0`-@`Q`````0`````````````````````````!``````````````#8````
M/P`````````````````````````````````````````````X0DE-!!$`````
M``$!`#A"24T$%```````!`````(X0DE-!`P`````!SP````!````<````"$`
M``%0```K4```!R``&``!_]C_X``02D9)1@`!`@$`2`!(``#_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"``A`'`#`2(``A$!`Q$!_]T`!``'_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#TCJ/5L+IWIMO<YU]^X8V+4TV76EHW/%%%<O?L_P`)9_,T_P"'LK8J
MO[0^LC_TE/2*F5?N9&6&70/^"QL?-QMW_H:@?5:IN739]8;PYV9U0N<PO,FK
M%:]S<+$I_P!'5Z/Z>W_2Y5UUJVLBBO(HLQ[9-=K2Q^UQ88<-KMME9996[^76
M[>DIQ<CZTLKZ5=FU8MGVO&R:<3(P+B&65V76TT`.=7Z['M=7DLR*+*?5KOK6
M\N.ZOTK*Z;F].R\G-OZA1=F8>+8',J:[VVE^#=GVX]5?VBO'R+'LJ_F?UB^B
MZSU?278I*<3J)MZIU=O166.KPL>D9/4C6[:]_J.=7A87J,<VVJJ[T,F_)]/_
M``=%5'\SDV;R?55P=T.C:2:VOO93N<7$5-ON9C5[W%SOT=#:ZVH'3'U4?6#Z
MPV7N#'`XMI<=`,<4;6.=_P"A%.<JOU/NS&5XG3_;]FJZ9C9=\CW_`&G,?=:Y
M@=.WTV-JL]FW\^I)3U"8D`$DP!J25&R^FIU;;;&L=<[94'$`O?#K/3KGZ;_3
MKL?M_<8N4^M'4K>I/_8_3[6^G9;]CL`EWKY+F[CA^T._4NG4_K_67?0LKJ_9
MG^&RZF)3TO3^H874L5N9@VB_&>7M9:V=KC6]U-FR?I-]2M_O^@__``:LH&%B
M48.'1A8XVT8U;:J@>0U@#&?]%J.DI228D`23`')*R\GZU?5K%>ZN[JF*VQIA
MU0N8YX,3_-,<ZS_HI*=5)8H^MO3+*Q9BTYV4UWT33A91!\Q99175_P""(F-U
MS+R2/3Z-GL82!ZEPQZAS]+99EB__`,!24__0[KZNO;B69?0;`VNW!M?;CL&Z
M'8F0^R_$M9O'^"FW"L_X7%_X2I;:H=3Z;9E^ED8MWV7/Q23CWQN;#MOK8^15
M+/6Q<C8SUJM[/YNJZJRN^FJQ5\?ZP4MN&'U>O]EYI<6UMM=-%T'1V#FD5U9&
M^?YA_HYO^DQ$E,_K/AWYO0<RG%G[4U@NQ0WGUZ'-R\4?^Q%-:I]<^L+Z^A8]
M_3BZO-ZHQAP]S"XTLL]/UL_(I#;-M'3JKO6O=8STO4]*JW^=70)MHG=`W`0#
MW@I*>%S\_IW4K<2OI?4'9#.I4?LCJ=EC'[V5^IZ565FL]&MN/E67?;<#$9D5
MXOKY74O6H_146+6Z/U'!Q<U['MVY'6NH95.-4P"&U].8<!Q/T=F.QO3O^WLM
M;>3TSI^7BY.'?0QV/FS]I8!MWEP#'/>YFU_J;6L_2_SGL65TWZKXM3,S'ZGB
MXV<S(M99]IL8'69`8/T3L^E[/1^TT>[]+5^CR=]F3Z5%M]U:2G`ZIUZGJ75S
MFX'4*<.K!#\7%ZF\U/HK%C2<_(+,C9]KLOL9BT=/Q\:SU/4Q/M=G^3\IC,V[
MT%]6!2'=,PL[K62*]K<IU(PZ&L<18^O%_:+\7]%?;^L9%U7V[*S+?TV7DY/Z
M+T^BP>@]$Z<6G!P,?&<R=KZZF-<-T;_T@;O]VUJOI*<0_P#/+)<('3^FU%NI
MF[-LD_R8Z54S;_6N2_YO9][=O4.MYUS9DLH]+$;Y#U,.FO,_]FUMI)*<8?4_
MZN&SU<C#;G6\>IG/?EN^`=GOR-K?Y+5IXV'B8E3:<2BO'J:(;74UK&@>#6,#
M6HR22E))))*?_]'U58OUT_\`$EUC_P`)W?\`4.7S>DDI^IZ?YIG]4?D4U\JI
M)*?JI)?*J22GZJ27RJDDI^JDE\JI)*?JI)?*J22GZJ27RJDDI__9.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`#8`+@`P````
M`0`X0DE-!`8```````<`"``!``$!`/_N``Y!9&]B90!D0`````'_VP"$``$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("
M`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`#\`
MV`,!$0`"$0$#$0'_W0`$`!O_Q`!I``$``@,``P$`````````````"`D%!@H#
M!`<"`0$`````````````````````$```!@("`@("`@(#```````"`P0%!@<!
M"``)$1(3%!8*(A4A,4$7&!$!`````````````````````/_:``P#`0`"$0,1
M`#\`[^.`X'B//(2D'*5)Q2=,G*,/4*#S`%$$$%`R8:<<:9D)91118<B$(6<8
M#C'G/`P['*(S)RU!L:D3%(2D@P%JC6-W;W8M,8:$0BRU`T"A0$D9@0YR'`LX
MSG&,^.!G>!IH;%KX5@&U.&=PT5ID1%/8!]:!D[)FP"8&K=U4>238V&X7?D1<
M15/Z$]"6Y9381C6$C)P9DP`@X#<N`X$8MR=L*RTBULM39FV3E!D7K2.GN"2.
MMAJ;$EGLK5B"@A]=0U*J,+"Y3"<R-0G;6\C'G(CS\"%X`$8L!0)MQ1/8G,=#
MMA^S+9;:C8'7;9JDZ.LK:'6S3C6B;-,-IK5(J$L;A831!;L4I(^</;::D1=@
M3$2Y5)2LLI1PG)*V(B4I@1Y#ISACX=)H?%)(H(*3*)#&F)\/3$Y&(E.<[-:5
M>:04(><C$44-1D(<Y_SG&/\`/`V7@.`X#@.`X#@.`X#@.`X#@.`X#@?_T.\>
MP[#@U2P27V?9LL88)7D`CKM+9I,I0XIFB/1F-,2,UP=WIX<E8RTZ-"@1D"&,
M8L_ZQXQYSG&.!3<AVVWK[&U("^NR+L^K>G+VC<"4?8GL7`SY%/K+2_Z1R;47
M520+XZM<HZH,)Q].46"6B:5R=1E0E;%020X/#:VWH]U5G4=(3;J6/M/V#S$U
M,GPY2;:'92WE472JS4987LB&4[7$M@=3Q"/.;D-2>4E_JEJM,0J&ERL-3_QR
M&)0?KZ=8<"&M?];ZJL_3RUAH5*)DO+5?8V^ZLM2,84C*,,RW.`;#>(R\H1F$
M`R8W/36Z-1_KCY4H_&/`;%IY>>Q6MVS8>M#=Z>*KG?I!`9-:FCVX;JU-4=>=
MF:L@JYM*L>J;?1HU*-I-V?HTF2(3E1C,CRGD<3^-Y4A3K`J_F"L372$6%*?V
MZ^P"P5!;J\0"J=$*HC1;DK5X,;8>98$-UN6QR,-Y)AN1DER!V:I,Y`*+!\>3
M@JS19P(7\@ZQN`X%"NYJEDW'[A="]$5H';$0TVABKM<M)2A/)&V.TXA<T!3^
MM$2<2#P`)),:)B\N3\?XR>>,H"?`"RP9,."'W'OQE`(?TX=A3L,[X`J]>G^+
MX'ZKA>PYPZLL*+)\-X@GX^R9(,%^19^#'MY.QDG!F,A;!'&1/&8\PQM&:>>D
MC[*ULB4]3DO*@Y.U(2$!!JC)0"RLGF%$8R/U"$/MG/C&,?XX&9X#@.`X%*FV
MO=-5%%[ZZU=:E%5TNVFVUNFR8XPV?"8I,&Z*-6O%:KV<N7OTUFS\X-;JD<)8
MW5_\S^GCA?P&C:$QBE4J2?*A+7!=7P'`<!P'`<!P'`<!P'`__]&_F[XBL[7N
MQ^3:I3(A:NZ[NN(^J[`O-I;2THXQLWO*^81SF$43/UJPA>US*I*6K)>G=9+&
MR<8P-[=4I+L#(?I8`%_*=.0D((2I2"4R5,26G3)DY8"2$Y!(`EDD$$EA"642
M46'`0A#C`0AQC&,>.!YN!!O??5:Q]HJMB&*+O22:[;$TA9#-=E"V,W",<H3F
MPHZT/C(7%+C@XRST5@5-+661*T;HWC!@\K(RU)`O<CXC0I6W!6]YDNJFNW1^
MZVM9;'VWU'L-!?U)[54)M.TI:P4/<*2J6N>1H-%V:Q1:[#V:^JI<'N-+(^D?
M0A5?VA!@U:8Y*0(`2%Z2@2N4W!V)W;<%O0382\[SE.G%IO5PUS`5U>0@^JK"
MT\K2<U+7,&CZY_DQJ:&UNDD3@@2'&JO[%S]<N#@`"M4,(0Z".`X%%&H:,$N[
MY^XJ7.`L@7T_KOUO5)'BRV\Q&6<P61";:M!X.4J1!+`[*2GMG+"!0'!F`EBR
M1[!R2(/`VO\`8&0*IQUJS37II3"52C;F^=2M5H@'[)J-,7(K?V7J]M*,7JR&
M]T/3(LMR)2`8RR##`Y%CT#D?KC(37MO=.,U/NSJ!I0JAKN_2K;>&;%S1MEZ!
MR3$-<`;]?(Y%9`?A_:SD@U#B5,OR,Q,D,(/!]<])GY`BP8'.`FKP'`<"M'L1
MW"GM+MD"UGU5:TLYWSVJ6'P^@XR)$0^,50QX1Y+?-ML+N;@"/4L]&4BC5_:4
M'C3*,/#T)$U%%&"4FB)"J[I>TZA/_K;9+8UN?Q6/'=1WFP-+(K:<A(&XRR_]
MP)$=!ISV*[@2!Y<E*]7AUG%F(FV%L04IN42&.,!R-/@!7O\`*'3_`,!P'`<!
MP'`<!P'`<!P/_]*^_P#70:S"]:MX):[JAGSRR^V'>Z<VBG,6Y6&MM@&3*-Q=
MR1&Y&I6'D&":HNB/R$TTPP>3_ER(6#,"R'03P'`<!P.7[I<J20:<=IW<QI:Y
M2=>[0-K<=:[QU];7YR6NK@WT=-&2;?B<8C[B]FFOB^+5&V.J.(8P(9I*4QJ`
M$(O`PB,#J!X#@47PYP7T=^PQ=446,IS/#=\NN>J+*8Y*`PL#5,;>T^M*50%^
MCIF%&`GJ)1':NM5&K$!/Y**;3"Q#\B'GT#?>S*2-LUV]Z:]2C3#L+K5W@E.R
M[B1C'LA51#1F@;&MSXG$04RDPD)%K/\`#U286,%X$L3%`R,.!Y\AH5?1T>Q'
M[`5[70W.B1RKOK_T(K36$Q"(2=46EV.V;L>171)UK(L2(S0!71^F(VTH7A*>
MJ">E$Z),A*]3S!<"]#@0+[`NPBGNO>K8],)XV2.Q;0M&6-%;:[Z[UVE&Z6WL
M/:C^],;$UP&N&<L@_"ER^U($YB@XW&"B2A8QCW.,))-#>]I]PX)J!J^\;)V[
M'Y(B4IF>.(HO3K44G?+,L"XYSA*V5]0<,;F$;LE?K'F<T7D,J;"89R(LX0U)
MIP$1)R@`4"3<O8/6-E+=E#%_V5^P)VVI'F`,0V%>JG$<Z^]=I'(4_P!H]M=$
M.'@,#U<U`0KF]4M6$`4AEL](*/-RX@`(Q.'17J5KC$-1-::5ULA!GW6.H8"R
MQ50_FI@I7&:R<!0E\XL60!"8=D^665-5S@_O"@9AAJIT<E!PQC&,0LA(G@.`
MX'C..)3$FJ%!I1"<@HPX\\XP)1)))0<C----'D("RBP!SD0LYQC&,><\"NBU
M^WWJWI%T6L-E;_:HLDA:UQK8[QINNB%RR3,K@0((#D3Y'(<Z/[VRJB1"Q[`5
M$$B#_O./'`BDN_8,T0EOY$V:HQC;G?.7L#=A;^*Z?Z@WY8^%AQQ:K*0H,K>(
M3%860@-.3A`-?EP$C+P9YP8+)9H0!C8GVC=CMS(3'BA^B7:DMB#A6FPOVKV"
MH/4-T)<BD7S)`*(3-U$FG1K6J6EC)$K2MRD)>/C'ZYP/.`![L7LK]B>QG1R-
M,UEZNM;6`D@8D*>U[LORZ)$<<KRI&C+)Q3[,R,ZW#2$!8%F3CF[!PA>Q&<XR
M()89@W4_O#L`\]9,>V^@Z(+$J<!E,6N77G"Y>2$A4+[*,!<@V%M*;J""VTY0
M-,`L:%288F3%#,/&<8:+`:ZEZDMSI:O7K[P[T>P^1C>3"S7<FBF2@-:DWR$F
M8$7_`$"*.5U+VZ*DY*))",M$06`P03,BQG!P@X"5E:]6E*01S89#)]@.PN[I
M/'7%H>4;W<G8KN.[HE+LSOC=)"E3C`X?<$(JQ:@5O3.D.4-8F'^F-PG`7]3!
M6/3(?__3Z.M"G>(ZR]F/9SH&B9%$<16Q,HKVA4R$:@U0C?([L#%H96&Q:5`7
MD/P-2>/["UXH<"DX!!",,B,P`L.$XS#0N^X#@.`X%".UB\C6WO>Z[-A'10%A
MA6XNLUYZ`2I]R0N/0+IY&I2U7]2,><P)S#4J1S?'\3BD;50B0F>QAQ(C,E"%
MDH+[N!SG;6;L;@;'=O\`2?6)H/.AUG7&OJ")WWV.W^U09FF"F(L9QJ670N@D
MKC*TCA&VEPL-C3HDYY92<Y<K_(`B`,*=J=2A!]Z[K&67U;$=1^Q."B=?EZY-
MFF"Y+K2,)IH7UZT[G;6IKO:5G:4Q!Z8;JK(B*]$["1C'DD\EI'[`$,)>0A[N
MHLO9MZ=^[WW]9_PF3:KZUURIU`TKMQH4M3\RVF[OKJUS7<&Z(M)`K5Z#,8:Y
M;%V:%M+LVB`F<$[4[8P:,L8\9#U>B:!_=UDNW<IQ-,5R#LAW`V(W1(.5'JE"
MQKK&>3=9'*2BN,K,"/2-K+6450J$R3)A_P!3"\96#,X#@(0NTX'*SV0053V%
M;37A;M9["UW0K+T=1:OY+4-YVX(3?1,<[`GRP89>=NI;2<DYJY+*JXKR@:TC
M$==@#)P<RO,P59*)4GIADY#XG6\E[\^PB_Z;VLD.@>L](5^SU+%))IW+-AKU
M2S*C:2?K!8?O3?9YTU_A3@9>T\V`E<17`;X8G?4$8#"FU:>D5E?95+E@@OST
MHZ\8+IP^6I?=BVM*]F=NKM*&MOG;2WT4>:I*ZM2=8-X,A=>1]J*PR4C2+6I*
M)-311I/_`*Q/A$FR:(W*4@108G:;N5ZP=-$`5-];GTNSNIN1!3PR$/YEO6&:
M+`#LE#-@%2I9K+6U$H,($6!8L2)D/RXR$1P<XSX"'3;WZ0V\!%)=#.O;L9W;
M`XI,FLUD1/7\RF]>#EP"#33F9XNRZGB)I&)Q(&$`<X&UFECP+.2AF9#ZY#))
M+>_8QN]L.<H9I[UN:.D*CC"`L6S^Q5I[+3]K2&!"7A<C%K3&FBOW%<3G`C"L
M*%Y)7D0/D*S@(@##U6[K>[9;PCB!FW&[J[,B;.<K2.#W#]!J&JO6]]+.`D`$
M]&V;`KVE_L4:0@]0H++QAM2$'!"6<>G&9@`20_`/UO.O"4_V>=B)5NEN`-U=
MD3PJ'LSN?><MP,Y'\?@@\B&R2`)7(E0(K&3!K"U*C_@!@`^,8"P>K>KGK:I0
M30HJW0O4*'.S&E^FW2=NUZJP^:@(^R!7X53EPC"R8.)GV2@#^12N-,\E@_E_
M`/@)TDDDIB2DZ<HI.G3E%DD$$E@*)))*!@!1110,!`646`.,!#C&,8QCQC@>
M7@.`X#@.!__4ZF>TG7>WY&QTYNQJ@D&OVZT/D3]9<)A1!OTP[$4L^(V_%_:L
M.B\)9XD1=N1N/)#&M5\"@Q(^MB3XP8^4P6`F7J#M94>[>N56;-TB\#=8%:,<
M3/"=&LP44_1-])R)'*('+D)1AN&N80B0)U#8YI_80`*DP\EC,*$68,)*<!P'
M`JX[=-(K/WHU@B4/H671N";#4;L;16T5#2J7J5B&-M5D4Q+@N!`G-P;F21+D
M'SQIU<BTYI:)1@*P1/R`R5[\"56Y=CW]4VL]J3C5FEA[";#H6QE9JBJ?+VV1
MQ`_3*82IAAK>[R!Z>5C<VH(C!@OXW]Y$8I3>S2UJ`A.*$()@0H9HKK'[D-+H
MEM](-?MO-/;0OK=!P:;SM>[[@H^8%V]'[V3P=>@?81`!-\HS6\DKE)(AA*B!
MC^D2H(\F5J,C:A@&(&0QU&RCN![$]481HQ=]!VGJB@S!BJF[&-TMFD5=1JP[
MBCCN%?&[=K;3JIH-&G6-O+G/X<["3)+!<"4K(W(PGC++5N623AAN.G33/:BT
MZ[!.BU^0@=-AM3-9KP:M6WUS;6YF0[3:LWM%;"#1UEL;*U)4)[F]0J5R,N'3
MOZ2920C?@I\C5'J%^0A"%`]R7;8#I@UZZU>KB0.TKVN)ZZXP@V><88U2!^=-
M2H?4M"*/^UX+.S6]&M,8[_OBS(@IKN.1H(P/(#GQ2Y%%IRD2<8PUK9/]F77G
M5GKSUXJ'3;%A6%<A=0UWKQ(;KD].6A'ZLUHF\*K"/,<S"\XL"-Q,^U+LB&$X
MS&^+HS0H#%9>#W)P(3`P2K#X!HK;!5R4K1(+'U#[(-R-?BI7(KPJW5"F=3GI
MOKFX;K;IJ_V.^;;]D&SERMU35)<]AV[8+B3(V")0J22&#,"$M`A7`>EP18$'
M0>H=N_;:8LLR.1S2_JUK9^1+B?FFZQ[W9VWB^3#G=*W.Y;/'3(;K&@<1)`)%
M7T#U3\408;C!IQGQFIA!XD'1A!;A9`-_8_N?NGV-%G'C7+:_LFYI-1VN@'8M
M0O\`Z]Z:J)U[=H&@+<T3>N$G]G%U=2Q`&:$("R3<DA"PG5OKQT?TI:B&K5K5
M^H*<&0>I4YD$=BB59.51ZM.<D/,<K$?\O$\=<Y1J#"`X4N1V`$#$6'&`9R'@
M3+X#@.`X#@.`X#@.`X#@?__5[^.!1U>^J>Q.BVPU@;Y]<<,':D(N)X/F&]/7
MFB>V:'M]TOB9D*;/_0VL:I6SG,<1V62%D85R!L.$G36*63@LT\MTP0::%BFH
MN[NM.\<`56%KG8J:5IV1U6QN<0YX;72(6=6,O:3OJO4,LVMY.D:Y?"9*SK@B
M)-)6)0%F"#[D&'%9"8()8\!P'`<!P'`KPW^TA==I&:NK8H^=IZ,W<UE=7J9Z
MJW_E`:XI(X]/2$I%+:QL5H(%C\JI.X&I(6U25M-+4>$^0*B"Q*$X`C#%]>-\
M#M)%;$&L[45;IKM[7:F%/>U,"305I;(%/97.R90A9;BJBV(UA7'KLKR<+8&[
MX1.(UI[TW92#2.199H2S#PGO(8%!9<!J+E<+B<G+8GK,D9`2&.,[T!FD62E1
M&7YJ"Y(U.&]ZR0N/!]HGT/\`0X>/;P,7D-LX#@.`X#@.`X#@.`X#@.`X#@.!
M_];OXX#@4_[1:CZ-[+;2N+C5FR4;U<[78G6F?QVT=>;?B33LXQP8(DRM`=;F
MOID@/9[NJ8XW*8M4DE\?6DF(<A*2+$0_A/+#(1>]NT?7>60R`[.ZPP'<.O)5
M9T3KQOVATM>#H3*XVP2E<D:R;`O/5BTUZK,89H\>HR<].47F3VD(3%&'X1IP
D>I?`MPX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
